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1.0 The Burden of Cancer 
Cancer is a global phenomenon transcending the boundaries of age, race, geography 
and socioeconomic background. Today, cancer accounts for about 1 in 7 deaths 
worldwide – more than HIV/AIDS, malaria and tuberculosis combined [1].  In 2012, 
there were an approximately 14.1 million cases of cancer diagnosed worldwide with 
8.2 million cancer-related deaths. In addition, the global cancer burden is growing at 
an exponential pace; in 2030 alone, approximately 21.7 million new cancer cases and 
13.0 million cancer deaths are expected to be diagnosed [1]. 
The causes of intractability include advanced stage disease at presentation 
which limits the application or effectiveness of treatments, resistance of tumour cells 
to chemotherapy and radiation therapy, anatomical locations of the cancer that 
preclude complete excision or ablation by radiotherapy, and the presence of 
intercurrent illnesses which either limit the application or adversely alter the risk-
benefit profile of any given treatment [2-6]. 
1.1 Conventional Cancer Therapies 
The ideal treatment of cancer should effectively control local disease, be applicable 
to a diversity of tumour types and anatomical locations, be effective against locally 
recurrent disease, facilitate multimodal and systemic therapies, be minimally 
intrusive and improve patient wellbeing and life expectancy by tumour control or 
cure.  
The most effective treatment strategies are those which provide healthcare in 
a sustained and equitable fashion,  are linked to early detection, and which adhere to 
evidence-based standards of care and a multidisciplinary approach. The principal 
methods of treatment are surgery, chemotherapy (including hormonal manipulation) 
and radiotherapy. Although each has a well-established role in its own right and can 
cure certain types of cancers, multidisciplinary management is more effective than 
sequential independent management of patients [7-11]. 
1.1.1. Surgery 
Modern medicine has seen a move away from interventions of the past which were 
‘primarily surgical, primarily heroic, and primarily unsuccessful’.  The field of 
surgical oncology has emerged as a specialist discipline with recent advances 
including more precise identification of tumour margins, leading to reduced local 
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recurrence. However, while surgical resection has proven to be effective in the 
control of primary tumours and early-stage disease, its contribution to the 
management of regional or metastatic disease is significantly attenuated [12-17].  
1.1.2 Chemotherapy  
Despite the existence of an array of chemotherapeutic agents, cancer survival rates 
for clinically advanced malignancies have improved little during the past three 
quarters of a century. Among the limitations of conventional chemotherapy is the 
lack of tumour sensitivity to existing chemotherapeutic regimens, as well as the 
development of drug resistance. The mechanisms responsible for this refractivity 
include a reduction in drug uptake, enhanced drug export, intracellular inactivation 
of the effective agent, alteration of the molecular target, an increase in the activity of 
the target route to be inhibited or the appearance or stimulation of alternative routes, 
enhanced repair of drug-induced modification in the target molecules, and 
activation/inhibition of intracellular signalling pathways, which leads to a negative 
balance between apoptosis/survival of tumour cells [18-24].   
1.1.3 Radiation therapy 
Radiation therapy has been in use as a cancer treatment for more than 100 years. It 
has been estimated that between 50-60% of cancer patients will benefit from 
radiotherapy. The major indications for radiotherapy in anti-cancer strategies include 
head and neck cancers, gynaecological cancers (e.g. cervix), prostate cancer, pelvic 
malignancies (e.g. rectum, bladder), brain cancers, and as adjuvant therapy in breast 
cancer [25]. Radiotherapy is also routinely used in a palliative context, to reduce 
pain and address acute symptoms such as spinal cord compression. 
While radiation therapy in itself is painless, it is associated with a significant 
side-effect profile. Although most radiotherapy side-effects are predictable, the 
nature, severity, and longevity of side effects depends on the organs that receive the 
radiation, the treatment itself, and the patient [26-30]. 
1.2 The Need for Novel Therapeutics  
The more we discover of the molecular diversity of tumours, the more we realise that 
cancer therapies need to be engineered towards molecularly-defined subsets of 
tumours [31]. Moreover, the advent of more targeted molecular therapies has been 
countered by the ability of the cancer cell to mutate or employ epigenetic disguise. 
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There is also little doubt that it is in the transition from laboratory to clinic where 
most is lost in translation. 
There is now renewed optimism that many cancers can be cured or 
forestalled by immune-based therapies used either alone or as part of multimodal 
programmes [32-36]. This has resulted from an improved understanding of tumour 
immune interactions, and the viability of cell, gene and ligand-based technologies to 
promote effector anti-tumour immune responses.   
  In this chapter, I will examine the literature reporting research into the 
conceptualisation and development of electroporation and systemic gene and 
immunotherapy anticancer treatments since these areas are directly relevant to my 
work. For each of these therapeutic modalities, I will explore both their present 
utility and the current limitations to their clinical application.  
 
1.3 Electroporation  
1.3.1 Principle  
The cell membrane represents a physical barrier to the intracellular transfer of 
hydrophilic drugs, macromolecules, nucleotides and peptides. The phospholipid 
bilayer of the plasma membrane restricts the transmembrane movement of 
hydrophilic and polar molecules, other than by specific channel or receptor-mediated 
assistance. The application of electric fields has been utilized to overcome this 
barrier and permit the traffic of various molecules. This strategy is referred to as 
electroporation. Short high-voltage electric field pulses, optimised to balance the 
reversible and irreversible effects of the procedure [37, 38] (Figure 1.1)  are used to 
render the cell membrane transiently permeable or porous [37, 39]. Using this 
technique, a wide range of molecules, e.g., ions, peptides, oligonucleotides, RNA 
and DNA and hydrophilic drugs have been successfully delivered intracellularly [40-
43].   
1.3.2 Pulse parameters  
In clinical practice, optimised pulse parameters (8 square wave pulses; amplitude 
1300 V/cm; duration 100 ms; frequency 1Hz) are utilised to permeabilise tumour cell 
membranes (Figure 1.1). Using these pulse parameters, drug dosages that have 
minimal or no anti-tumour effectiveness demonstrate high (75%) complete response 
rates in treated tumour nodules [44-46].  
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1.3.3 Pulse generator  
A number of pulse delivery systems are commercially available including the 
Cliniporator (IGEA) and the MedPulser® (Inovio). However, for the purposes of this 
thesis, the ePORE Gx was used for optimised pulse delivery (Figure 1.2).   
1.3.4 Electrode systems  
The electric field distribution is largely determined by the geometry of the electrodes 
and these can be divided into two different types: plate electrodes and needle 
electrodes (Figure 1.3). Plate electrodes are suited for use in skin or superficial 
lesions. Needle electrodes are either arranged in two parallel rows or in a circular 
(hexagonal) array. Unlike plate electrodes, these are impaled transcutaneously into 
the target tissue. Regardless of the type of electrode, the electric field is highest 
around and between the electrodes. In addition, different tissue types will have 
varying degrees of tissue pliability and electrical conductivity. This needs to be taken 
into consideration when deciding which electrode design to use in any given 
situation.  
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Figure 1.1: (A) Electric field applied to the cell membrane; (B) When external 
electric field reaches a threshold value, the cell membrane is permeabilised to deliver 
drug/biomolecules inside the single cell. After electroporation, the cell membrane 
reseals again [47]. 
 
 
 
 
 
 
 
 
 
 
 A B 
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Figure 1.2: The ePORE Gx, clinically approved pulse generator used to deliver 
permeabilising electric pulses. 
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Figure 1.3: (Top: L – R) Plate electrodes; hexagonal array needle electrodes; 
parallel array needle electrodes. (Bottom: L – R) EndoVe, a novel electrode system 
designed for delivery of electroporating pulses to gastrointestinal tissues and 
tumours; ThoraVe, a novel electrode device designed for delivery of electroporating 
pulses to pulmonary tissues and tumours. The choice of electrode used for 
electropermeabilisation is influenced by a number of factors, including tumour 
locale, the pliability of the tissue to be electroporated, the likelihood of encountering 
resistance (e.g. previously irradiated skin) and physician preference.  
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1.3.5 Electrochemotherapy  
Electrochemotherapy involves the local application of pulses of electric current to 
tumour tissue rendering the cell membranes transiently permeable to otherwise 
impermeant or poorly permeant anticancer drugs such as Bleomycin or Cisplatin, 
thereby facilitating a potent localised cytotoxic effect.  
              Studies have been performed in a wide variety of tumour types, including 
melanoma, hepatocellular carcinoma, lung carcinoma, breast carcinoma, 
fibrosarcoma, and glioma [48-52]. The cytotoxicity of Bleomycin has been shown to 
be increased by up to 700-fold resulting in objective response rates as high as 90%. 
The ESOPE study (European Standard Operating Procedures of 
Electrochemotherapy) was a prospective, non-randomised multi-centre project 
funded under the European Commission’s 5th Framework Programme. They assessed 
treatment outcomes following electrochemotherapy based on tumour histology, 
chemotherapeutic agent, route of administration and electrode type.  Patients were 
recruited from four centres, namely: Institute Gustave-Roussy (IGR), Villejuif, 
France, Institute of Oncology Ljubljana (OI), Ljubljana, Slovenia, University of 
Copenhagen at Herlev Hospital (HH), Herlev, Denmark, and the Cork Cancer 
Research Centre Biosciences Institute and Mercy University Hospital, National 
University of Ireland (CCRC), Cork, Ireland. Electrochemotherapy with Bleomycin 
revealed an objective response rate of 85% (73.3% complete response rate) [45, 53]. 
Electrochemotherapy with Cisplatin resulted in 77% long lasting complete responses 
of tumour nodules. This held true over a variety of tumour histologies, drugs and 
routes of administration. There was also a trend towards higher anti-tumour activity 
in non-melanoma nodules (OR 90.4% versus 80.6%).  
Electrochemotherapy is now used in the treatment and palliation of a wide 
histological variety of tumours. The encouraging clinical experiences to date promise 
the development of systems for treatment of intractable deep-seated malignancies 
[54-62].  
1.3.6 Present Limitation of Clinical Utility 
Until recently, the full clinical utility of electroporation has been restricted due to 
limitations in electrode design. Modification of existing designs to allow for 
attachment to conventional endoscopic and laparoscopic equipment would allow for 
the clinical license of this therapy to be greatly extended [63]. If it were possible to 
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deliver permeabilising electric pulses to luminal tumours e.g. intra-abdominal, intra-
thoracic and genitourinary malignancies, tumours that would previously have been 
unresponsive or inaccessible to conventional therapies would be amenable to 
electrochemo- or electrogene therapies.  
In this thesis, we will describe the development and validation of an 
endoscopic electrode device, the EndoVE, designed to extend the clinical utility of 
electroporation to the management of luminal tumours. If this system proves 
successful, many otherwise intractable or inaccessible tumours would be rendered 
amenable to treatment.    
1.4 Cancer Gene Therapy 
In 1989, Rosenberg et al performed the first human gene therapy trial when they 
used a retrovirus to introduce the gene coding for resistance to neomycin into human 
tumour-infiltrating lymphocytes before infusing them into five patients with 
advanced melanoma [64]. Since then, over 1700 clinical trials have been completed, 
are ongoing or have been approved for use worldwide [65-70].  
1.4.1 Present Utility of Cancer Gene Therapy 
The aim of gene therapy is to introduce a defined DNA sequence into specific cells 
in order to replace a defective gene, or to impart a new function to the cell in order to 
induce it to secrete a therapeutically-functional protein. In practise, Figure 1.4 
demonstrates the diseases in which gene therapy has been approved so far. 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
 
 
 
 
 
 
 
Figure 1.4: This figure illustrates the clinical targets for gene therapy In practice, 
65% of gene therapy clinical trials have been directed towards the treatment of 
cancer [71]. 
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1.4.2 Viral Vector Delivery Systems  
Generally speaking, clinical trials have thus far utilised two methods of gene 
delivery: viral and non-viral. Currently, viral vectors are considered as the most 
effective of all gene delivery methods for in-vivo gene transfer  [72-83] As such, it is 
not surprising to find that they have been the most frequently used vehicles for 
transferring genes into human cells (Figure 1.5).  
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Figure 1.5: Different gene transfer vectors used in clinical settings. By far, 
adenoviral, retroviral and naked plasmid/DNA have been the most commonly used 
gene transfer vectors [71]. 
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In most of cases, the viral genome has been genetically modified to make it 
replication-defective and non-pathogenic. Having established this, it is important to 
remember that the mammalian immune system is designed to recognise and 
eradicate non-self proteins.  As such, viral gene therapies are always at risk of 
stimulating the immune system in a way that reduces or even counteracts its 
therapeutic effectiveness [84-87]. Furthermore, the phenomenon of immune memory 
results in an enhanced response to previously encountered proteins / antigens, 
making it difficult for gene therapy to be repeated in patients. Moreover, viruses also 
present a variety of other potential problems to the patient including toxicity and 
insertional mutagenesis, as well as posing gene control and targeting issues [88-90]. 
In addition, there is always the fear that the viral vector, once inside the patient, may 
recover its pathogenic traits and cause disease.  
1.4.2.1 Alphaviruses 
Alphaviruses are the major genus of the family Togaviridae [91]. Characteristics that 
make alphaviruses attractive candidates for development of replication-defective 
viral vectors include: 
1. Recombinant alphaviruses induce high-level expression of encoded proteins 
2. Following 48-72 hours of protein expression, infected cells die by apoptosis 
resulting in apoptotic bodies containing high levels of the transgene protein. 
This could be beneficial for the induction of immune responses via cross-
priming [92] 
3. Recombinant alphaviruses activate both the innate and adaptive arms of the 
immune system. Infection of cells results in dsRNA intermediates, known for 
their immunopotentiating capacity [93] 
4. In general, humans do not carry neutralising antibodies against Sindbis virus 
(SINV) or the Semliki Forest Virus (SFV) that may adversely affect the 
efficacy of immunization. 
Of the alphaviruses, the Semliki Forest virus (SFV) is the best studied [77, 94-99].  
In its replication-deficient format, the SFV genome is split into two plasmid vectors. 
The expression vector contains the non-structural SFV genes (replicon) and the gene 
of interest, while the helper vector contains the structural proteins. Due to the lack of 
structural proteins in the SFV replicon, no further virus production occurs, resulting 
in high safety levels for in vivo applications [100]. 
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1.4.3 Non-Viral Vector Systems 
While viral vectors have been shown to achieve high rates of transfection, they are 
also associated with a number of side effects, some of which are potentially lethal. 
To this end, various non-viral vectors have been designed and developed. Non-viral 
methods include physical methods such as electroporation, microinjection, gene gun, 
sonoporation, hydrodynamic gene transfer, cationic lipids and nanoparticles.   
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Method   Advantages   Disadvantages 
Needle injection      Simplicity and safety            Low efficiency 
 
Gene gun     Good efficiency             Tissue damage in some  
                applications 
  
Electroporation     High efficiency             Limited working range; 
                                                                                               need for surgical 
                                                                                               procedure  
 
Ultrasound                 Potential for site-specific            Low efficiency in 
                                        gene delivery             vivo 
 
Cationic lipids      High efficiency in vitro;            Limited activity in vivo 
                                        low to medium-high for               
                                        local and systemic delivery 
 
Lipid/polymer      Low to medium-high efficiency    Low activity in vivo 
Hybrids      in vitro and in vivo; low toxicity   
 
Table 1.1: Advantages and Disadvantages of Current Non-Viral Gene Delivery 
Vector Systems.  
 
 
 
 
 
 
 
 
31 
 
Electroporation as a physical delivery system is associated with high 
transfection efficiency. One of the principal benefits in using electroporation as a 
vector for gene delivery is that the electropermeabilising current on its own does not 
alter cellular / tumour growth characteristics, with resultant cell recovery and 
continued viability. This is an advantage for gene therapy, where therapeutic gene 
expression requires a duration of normal cellular function.  
A further advantage of electro-gene therapy is that the permeabilising pulses 
limit the distribution of the gene of interest to the pulsed tissue, such that gene 
expression can be localised and controlled using tissue-specific promoters [101]. 
When direct injection of naked DNA is followed by the application of electric 
pulses, enhanced, long lasting transgene expression can be observed relative to gene 
transfection methods without electroporation [101]. A previously published study by 
Mir et al (1998) reported increased levels of reporter and therapeutic gene expression 
that persisted for up to 9 months in mouse, rat and monkey models.  
Preclinical models have shown the ability of this non-viral vector systems to 
express sufficient amounts of therapeutically active compounds within tumours, 
enabling reduced tumour growth or even complete regression. While the transfection 
efficiency rates of electroporation compare unfavourably with their viral 
counterparts, electroporation is associated with a much safer therapeutic profile.  
1.4.4 Development of a Novel Non-Viral Vector System 
In this thesis, we describe the development of a non-viral vector system that has the 
potential for clinical application in electroporation-based gene therapy. We report a 
proof of concept Enhanced Expression Vector (pEEV) which encompasses a viral 
replicase from the Semliki Forest Virus. We aimed to improve upon nuclear entry by 
the incorporation of a nuclear localization sequence. We demonstrated cytoplasmic 
expression of the vector. We also investigated the oncolytic capabilities of the pEEV. 
Furthermore we compared expression levels of the pEEV with standard available 
plasmids in murine and porcine animal models.  
1.5 Cancer as an Immunologic Disease 
The concept that the immune system is capable of recognising and eliminating a 
developing primary tumour in the absence of external therapeutic intervention has 
existed for nearly a century. There is compelling evidence in both animal and human 
models to indicate that a functional cancer immunesurveillance process does indeed 
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exist. Paradoxically, the immune system has the ability to facilitate tumour 
progression by sculpting the immunogenic phenotype of the tumour, accounting for 
the development of cancer in immunocompetent individuals.  
 
1.5.1 Immune Tolerance 
Shortly after World War II, Sir Frank Macfarlane-Burnet introduced the dichotomy 
of “the self” and “the other” in an attempt to decipher the science behind immune 
reactivity. Immune tolerance is the process by which the immune system fails to 
react to “self” antigens. It occurs in three forms: central tolerance, peripheral 
tolerance and acquired tolerance. 
1.5.1.1 Central Tolerance 
This process occurs during lymphocyte development in the thymus and bone 
marrow. As T- cells mature within the thymus, they develop a recombination of gene 
segments creating the two chains that make up the T-cell receptor (TCR) for antigen 
recognition. These TCRs recognise epitopes consisting of short peptide sequences 
(6-8 amino acids long) derived from body (“self”) proteins. These peptide sequences 
are nestled within a histocompatibility molecule, encoded by the Major 
Histocompatibility Complex (MHC) as follows: 
 MHC Class II for CD4+ T cells 
 MHC Class I for CD8+ T cells 
1.5.1.2 Peripheral Tolerance 
This phase represents immunological tolerance after B and T cells mature and enter 
the periphery. From a self-reactivity standpoint, these mature B and T lymphocytes 
are relatively, but not completely, safe. Cells which exhibit self-reactivity are 
controlled by peripheral tolerance mechanisms.  
1.5.1.3 Acquired Tolerance 
This phase refers to the immune system's ability to react to external antigens 
characterized by a specific non-reactivity of the lymphoid tissues to a given antigen 
which, in other circumstances would likely induce cell-mediated or humoral 
immunity. One of the most important physiological examples of acquired tolerance 
occurs during pregnancy, where the foetus and the placenta must be tolerated by the 
maternal immune system. Acquired tolerance plays a crucial role in the development 
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of the phenomenon of “oral tolerance”, implicated in the development of 
inflammatory bowel disease and upper gastrointestinal malignancies.  
The concept of “cancer immunoediting” [102-105], emphasises the dual roles of 
immunity in not only preventing but also shaping neoplastic disease. It envisages 
that the process of oncogenesis involves three phases: elimination, equilibrium and 
escape (Figure 1.5) [102-105].  
The “elimination” phase represents the original concept of cancer immune 
surveillance, which, if successful brings about eradication. This phase represents the 
complete immunoediting process without progression to the subsequent phases. 
During the “equilibrium” phase, the host immune system and any tumour cell 
variants that have survived the elimination phase enter into a dynamic equilibrium 
which is enough to contain, but not eradicate a tumour containing many genetically 
unstable and mutating tumour cells. The end result of the equilibrium process is a 
new population of tumour clones with reduced immunogenicity, derived from a 
heterogeneous parental population and sculpted by the immune system. The 
“escape” phase refers to a scenario where the tumour cell variants selected in the 
equilibrium phase can grow in an immunologically intact environment. This breach 
of the host's immune defences confers tumour cell resistance to immune detection, 
allowing the tumours to expand and become clinically detectable.   
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Figure 1.6: The three Es of cancer immunoediting: elimination, equilibrium, and 
escape. As indicated by the arrows, the immune system may eliminate the tumour in 
either the elimination or equilibrium phases, returning the tissue to normal [106]. 
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1.5.2 The T Regulatory (Treg) Cell 
The existence of a dedicated population of suppressive T cells was the subject of 
significant controversy among immunologists for many years. However, recent 
advances in the molecular characterization of this cell population have firmly 
established their existence and their critical role in the vertebrate immune system 
[107-114]. Sometimes known as “Suppressor T Cells”, this is a population of 
specialised T cells that express CD4 and CD25 transmembrane glycoproteins.  
Although all cells regulate other cells in some way, Treg cells are exceptional 
in that their main role seems to be in suppressing the function of other cells [114, 
115] (Figure 1.6) . This is achieved in a number of different ways including direct 
cell-cell contact, mediated by inhibitory molecules like CTLA-4 to cytokine-
mediated inhibition via molecules such as IL-10 and TGF-β (Figure 1.7).  
While the immunosuppressive potential of Treg cells may be harnessed 
therapeutically to treat autoimmune disease and to facilitate transplant tolerance, 
these cells very much represent a ‘double-edged sword’ in that their suppressive 
function may dampen the immune response, adversely affecting control of both viral 
and bacterial infections [114]. Crucially, this suppressive function may impede 
effective immunesurveillance of tumours. Thus, while depletion of Treg cells may 
disinhibit the immune system allowing for heightened tumour immunesurveillance, 
leading to tumour rejection, this depletion may concurrently increase the risk of 
developing autoimmunity [116-121]. 
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Figure 1.6: A reduction in CD25+CD4+ Treg cells or attenuation of their suppressive 
activity may elicit autoimmunity, tumour immunity, microbial immunity and allergy. 
In contrast, an increase in the number of Treg cells or augmentation of their 
suppressive activity may establish transplantation tolerance [115]. 
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Figure 1.7: Tumours may develop a number of mechanisms to suppress anti-tumour 
immune responses, such as the dysfunction of DCs, apoptosis of effector T cells, 
increase of immunosuppressive cells, production of immunosuppressive molecules, 
down-regulation of HLA expression, and presence of CSCs [122]. 
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1.5.4 Granulocyte Macrophage Colony-Stimulating Factor and the Human B7-1 
Co-Stimulatory Molecule  
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an important 
hematopoietic growth factor and immune modulator. GM-CSF which has profound 
effects on the functional activities of various circulating leukocytes. It is produced by 
a variety of cell types including T cells, macrophages, endothelial cells and 
fibroblasts. Although GM-CSF is produced locally, it can act in a paracrine fashion 
to recruit circulating neutrophils, monocytes and lymphocytes. Costimulation 
mediated by costimulatory molecules, such as B7-1, which are ligands for the 
CD28/cytolytic T lymphocyte associated antigen (CTLA)-4 counter-receptor, plays 
an important role in the induction of T cell-mediated anti-tumour immunity. 
1.5.4 Extension of Clinical Utility 
In Chapter 4 of this thesis, we characterised a non-viral vector therapy system; 
pEEV, with a vastly superior expression capacity when compared to a standard 
control vector. Having established this, we subsequently validated the use of pEEV 
as a gene therapy vector carrying murine GMCSF and human b7-1 genes 
(pEEVGMCSF-B7.1). We used electroporation as a means to facilitate the delivery 
of the EEV plasmid and assessed the efficacy and immune induction in primary and 
secondary responses to treatment in murine colon adenocarcinoma and melanoma 
cancer models.   
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Chapter 2 
Preclinical evaluation of an endoscopic 
electroporation system 
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2.1 Summary  
Electrochemotherapy enhances chemotherapeutic drug uptake by delivering 
electrical pulses causing transient pore formation in the cell membrane that enhance 
permeabilisation. The EndoVe is an endoscopic device developed to enable the 
intraluminal delivery of cell membrane permeabilising electroporation pulses. Our 
preclinical validation studies investigated the efficacy and safety of this non-thermal 
system in the treatment of gastrointestinal cancer models. Murine gastrointestinal 
tumour models were used to assess the efficacy of electroporation pulses delivered 
through the EndoVe in combination with Bleomycin. Tumour cell death, volume and 
overall survival were recorded.  Porcine and canine models were used to assess 
safety and efficacy. Murine tumour treated with ECT showed excellent responses 
with cell death induced rapidly via a largely apoptotic type mechanism. Application 
of the EndoVe to canine gastrointestinal cancer demonstrated successful local 
endoluminal tumour resolution with no safety or adverse effects noted. The EndoVe 
offers a non-thermal tumour ablative approach that presents clinicians with a new 
option for the management of gastrointestinal cancers.  
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2.2 Introduction 
The treatment of gastrointestinal cancers is managed primarily with surgery, in 
combination with other modalities such as chemotherapy, radiotherapy and small 
molecule targeted therapies to achieve local disease control and to reduce the risk of 
recurrence. Improvements in radiological imaging, minimally invasive surgical 
techniques and a new range of molecular targeted drugs over the last decade have 
supported a moderate improvement in five year overall survival rates. However, 
significant challenges remain for patients where the disease has spread, with the US 
currently reporting survival rates in the case of colorectal cancer at 40% with 
regional lymph node involvement and at 12.5% where the disease has metastasised. 
The effectiveness of many molecular therapeutic agents used in colorectal 
cancer treatment is also influenced significantly by their ability to access the tumour 
vasculature, enter into the tumour interstitial cell spaces and cross the cancer cell 
membrane. Physiological factors such as the presence of a high tumour interstitial 
pressure can impede to a large degree the ability of therapeutic agents to perfuse the 
interstitial space while absorption across the membrane is largely non-specific and 
requires repeated doses that can be toxic to both healthy and tumour tissues [1]. 
The technology of electroporation offers significant potential as a colorectal 
neo-adjuvant therapy in that it can facilitate both perfusion and absorption of low 
dose chemotherapy agents. Electroporation is a term used to describe the 
permeabilisation of the cell membrane following the application of a short and 
intense electric pulse. The permeabilisation can be temporary (reversible 
electroporation) or permanent (irreversible electroporation) as a function of the 
electrical field magnitude and duration, and the number of pulses [2]. It facilitates 
targeted chemotherapy absorption, referred to as electrochemotherapy (ECT), and 
has been increasingly employed clinically over the last 10 years. Positive outcomes 
have been published from the clinical experience in terms of tumour reduction, with 
an overall objective response rate of between 80-90% [3-7]with associated quality of 
life improvement.  
We have developed the EndoVe device which enables the endoscopic 
electroporation treatment option of gastrointestinal cancers. The EndoVe initially 
applies a vacuum directly to the tumour tissue resulting in a reduction of the tumour 
interstitial pressure, thus facilitating chemotherapeutic distribution within the 
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interstitial space. The vacuum also brings the tumour into direct contact with the 
EndoVe electrodes which deliver a set of 100sec electrical pulses to the underlying 
tissue. The electroporation pulse results in the tumour becoming extremely porous 
enabling chemotherapy drugs such as Cisplatin or Bleomycin to be absorbed up to a 
1000-fold more effectively [2, 8-10]. The benefit of this approach is that 
significantly less chemotherapy is required for a substantially more effective anti-
tumour response and the patient benefits from a reduction in the tumour without the 
side effects due to the lower drug dose used. Surrounding healthy tissue structures 
remain preserved after the procedure allowing wider margins around the tumour to 
be rapidly treated.  
The aim of the investigation was a pre-clinical evaluation of the EndoVe 
prior to a phase I/II clinical study. We sought to validate the efficacy of the system in 
the treatment of cutaneous murine gastrointestinal tumours cell lines and to assess 
the safety and utility of endoscopically delivered electroporation through evaluation 
in a porcine model and by treating canine colorectal tumours.  
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2.3 Materials and Methods  
2.3.1 Cell Tissue Culture 
Established colorectal cell lines CT26, CMT93 (Mouse), HT29, LoVo and CACO-2 
(human) were obtained from the American Type Cell Collection (Manassas, VA). 
CT26 and CMT93 cell lines were maintained in DMEM, CACO-2 cell line was 
maintained in EMEM, LoVo cell line maintained in F12:HAMS media, HT29 cell 
line maintained in McCoy’s 5A, all supplemented with 1% penicillin/streptomycin, 
10% (v/v) foetal calf serum and 300µg/ml L-glutamine at 37°C, 5% CO2. 
 
2.3.2 Animals  
2.3.2.1 Ethics Statement 
All animal husbandry and experimental procedures were approved by the University 
College Cork Animal Experimentation Ethics Committee and carried out under 
licenses issued by the Department of Health, Ireland as directed by the Cruelty to 
Animals Act Ireland and EU Statutory Instructions. 
 
2.3.2.2 Mice 
Female BALB/c, C57BL/6J and MF1-nu/nu mice (6-8 weeks) were obtained from 
Harlan Laboratories (Oxfordshire, England).  
 
2.3.2.3 Pigs 
Pigs (Landrace; n=20) were obtained from Teagasc, Moorepark, Ireland. During 
procedure pigs were anaesthetised by inhalation of 1.5-2 % Isoflurane delivered via 
oxygen as a carrier gas at a flow rate of 4-6 litres/minute. 
 
2.3.2.4 Dogs 
All dogs had naturally occurring intraluminal tumours confirmed through obtaining 
endoscopic biopsies endoscopically and subsequent histopathologic examination. 
Dogs were premedicated with a combination of acepromazine (PromAce, Fort 
Dodge Animal Health, Iowa, USA; 0.02 mg/kg) and Buprenorphine. General 
anesthesia was induced using Propofol (4mg/kg) and maintained with Isoflurane 
(oxygen flow rate 100 mg/kg). All animals received Carprofen (2-4 mg/kg) for pain 
relief. 
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2.3.3 Electric Field Modelling 
Electrical field modelling was carried out using FEM modelling. The electric field 
distribution was calculated without taking into account changes in conductivity due 
to electroporation – it represents the static electric field distribution.Voltage used: 
1000 V (FemLab).   
 
2.3.4 Tumour Induction and Growth Assessment 
For routine tumour induction, 1 x 106 CT26 or 5 x 105 CMT93 tumour cells 
suspended in 200 µl of serum free DMEM were injected subcutaneously into the 
flank of the female BALB/c or C57BL/6J. Tumour volume was calculated according 
to the formula V=ab2π /6, where a is the longest diameter of the tumour and b is the 
longest diameter perpendicular to a. Tumour growth curves were constructed using 
volumes calculated in this manner. Mice were euthanized when the tumour diameter 
exceeded 1.7cm3. Survival was recorded and presented as Kaplan-Meier survival 
curves. 
 
2.3.5 Drug Delivery 
The dose of Bleomycin (Mayne Pharma (Ireland) Ltd.) was dependent on route of 
administration. In murine electrochemotherapy studies, Bleomycin was administered 
intra-tumourally at a dose of 1000 IU/ cm3. In cases of canine electrochemotherapy, 
Bleomycin was administered intravenous (i.v.) as a bolus over 30 seconds at a dose 
of 15000 IU/m2 of body surface area.  
 
2.3.6 Electroporation Parameters  
Square wave electroporation pulses were generated with an ePORE Gx (Cork Cancer 
Research Centre, Cork, Ireland) square wave electroporation generator, and 
delivered to tissue using the EndoVe device (Cork Cancer Research Centre, Ireland). 
Eight square-wave pulses were delivered sequentially, at a frequency of 1Hz, for 
duration of 100µs each.  
 
2.3.7 Assessment of EndoVe-delivered Electrochemotherapy  
Efficacy of EndoVe-delivered ECT was ascertained by treating subcutaneous murine 
tumours. Prior to electroporation a surgical incision was made to expose the tumour 
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directly to the electrodes with the same steps followed for the control groups. 
Following electroporation, the skin was closed with absorbable Vicryl sutures. 
2.3.8 Histopathology 
2.3.8.1 Haematoxylin and Eosin Staining 
Tissue samples were fixed in 10 % v/v buffered formalin and embedded in paraffin. 
Serial sections were cut at 5 µm and mounted on slides. Standard H&E staining was 
performed on murine, canine and porcine tissue samples.  
 
2.3.8.2 Apoptosis Staining 
Evaluation of the tumours for terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick-end labelling (TUNEL; Roche) staining was utilised 
as described previously [130]. 
 
2.3.9 Statistical Analysis  
Experimental results were plotted and analyzed for significance with Prism 4 
software (GraphPad software Inc, CA, USA). P < 0.05 was considered significant. 
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2.4 Results 
2.4.1 Design and Electrical Field Modelling on the EndoVe 
The EndoVe was designed to incorporate two plate electrodes which were positioned 
parallel apart within its chamber (Figure 2.1). Electrical field modelling of various 
options demonstrated that the strongest, most efficient and homogenous electrical 
field was generated where the plate electrodes formed a lip around the outside edges 
of the chamber, enabling tissue underneath the chamber to also be electroporated. 
With the plates positioned 1.1cm apart, 1.0cm in depth, 2.5cm in length and with an 
applied voltage of 1000V/cm, a 100sec pulse was able to fully electroporate tissue 
within the chamber and underneath the device to a depth of several mm’s (2-5mm at 
1000 V/cm). Attempts to engineer a prototype with a depth of greater than 1.0cm 
resulted in reduced manoeuvrability and the prototype catching on the epiglottis. In 
clinical practise, the device was placed multiple times across tumour tissue to ensure 
full tumour tissue coverage with the total volume of tissue treatable with a single 
pulse calculated between 2.75 and 3.75 cm3.  
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Figure 2.1:  The EndoVe. A: EndoVe attaches to conventional endoscopy. B: 
EndoVe ECT in a porcine model C: Schematic representation of EndoVe ECT and 
energy applied. D: Electrical field modelling of EndoVe at 1000V/cm. 
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2.4.2 Effect of EndoVe Electrochemotherapy in Murine Gastrointestinal 
Tumour Models 
We evaluated the efficacy of the EndoVe as a novel ECT delivery probe by treating 
subcutaneously established CT26 and CMT93 xenografts (Figure 2.2). The 
outermost layer of the skin, the stratum corneum, is a resistive/non-conductive 
obstacle to successful electroporation of subcutaneous tumours, as it acts to dissipate 
delivered pulses [11]. For intraluminal tissue, this is not a barrier to treatment with 
electroporation. To assess the effect of intraluminal EndoVe-delivered 
electrochemotherapy, subcutaneously induced xenografts were injected intra-
tumourally with Bleomycin and then electroporated using the EndoVe. Tumours that 
received electrochemotherapy displayed significant tumour volume reduction 
compared with controls (Figure 2.2A and B). All ten tumours in the CT26 treated 
group (9/10 CMT93) responded in this manner with tumour reduction observable 
within 48hrs of the procedure (Figure 2.2C and D). Histological examination using 
H&E staining of tissue sections from ECT-treated tumours removed at necropsy 48 
hours after treatment showed extensive denucleation of the treated tumour tissue 
(Figure 2.3A i and ii), in contrast to the control group. H&E staining was also used 
to assess the impact of ECT on porcine healthy rectal and oesophageal tissues 
(Figure 2.3A iii-vi) 48 hours post treatment. Results demonstrated similar 
denucleation evidence as in the murine studies although not to the same extent along 
with some interstitial inflammation. Overall preservation of tissue architecture was 
noted along with an absence of any significant necrosis or haemorrhage. TUNEL 
staining for apoptosis in the murine ECT treated tumours was overwhelmingly 
positive (Figure 2.3B) and across a range of gastrointestinal tumour models tested, 
EndoVe ECT with Bleomycin was able to induce apoptosis in <6 hours post 
treatment (Table 2.1). 
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Figure 2.2: Therapeutic effect on established solid tumours. A: CT26 tumour growth 
curve. Each Balb/C mouse subcutaneously injected with 1 x106 CT26 cells in the 
flank. When tumours reached an approximate size of 100mm3 they were treated with 
Bleomycin (■), electroporation (▲), electrochemotherapy (▼) or untreated 
(●).Tumour volume was calculated using the formula V=ab2/6. Mice were sacrificed 
when tumour reached the ethical accepted tumour volume. 19 days post treatment 
electrochemotherapy significantly delayed tumour growth compared to untreated 
CT26 tumour (***p<0.001) B: CMT93 tumour growth curve. Each C57BL/6J 
mouse subcutaneously injected with 5 x105 CMT93 cells in the flank. When tumours 
reached an approximate size of 100mm3 they were treated with Bleomycin (■), 
electroporation (▲), electrochemotherapy (▼) or untreated (●).12 days post 
treatment electrochemotherapy significantly delayed CT26 tumour growth compared 
to untreated tumour (**p<0.01). C: Representative Kaplan-Meier survival curve of 
CT26 tumour showing response to each treatment. Survival curve shows 100% 
survival up to 150 days post treatment with all other groups sacrificed by day 21. 
Similar results were obtained in two independent experiments. D: Representative 
Kaplan-Meier survival curve of CMT93 tumour showing response to each treatment. 
Survival curve shows 90% survival up to 150 days post treatment with all other 
groups sacrificed by day 19. Similar results were obtained in two independent 
experiments.  
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Figure 2.3: (A) H&E staining of CT26 tumours and porcine tissue. A: i: Murine 
CT26 untreated tumour. ii: Murine CT26 48 hrs post ECT. iii: Porcine healthy 
rectum. iv: Porcine healthy rectum 48 hrs post ECT. v. Porcine healthy 
ooesophageal. vi. Porcine healthy ooesophageal 48 hrs post ECT; (B) Apoptotic 
death evaluated using TUNEL staining. Tumours were removed from mice 48 hours 
post treatment; Paraffin embedding and stained sections were examined 
microscopically. Samples shown represent i: untreated CT26, ii: Bleomycin alone, 
iii: electroporation alone and iv: ECT treated CT26 tumours. Apoptosis is indicated 
by the cell nucleus staining dark brown as is seen in the ECT treated CT26 tumour 
tissue. 
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                           CT26          CMT93       HT-9         CACO2         LoVo        OE19 
Untreated        3%               4%           4.30%        3%           2.80%            4% 
EP alone         5.60%         7.50%            8.10%         8.50%         6.10%        7.70% 
Bleo alone     4.30%          5.40%           4.90%              6%          3.60%          5.50% 
ECT 3hr      88.30%             89%              94%        99.50%       73.70%              80% 
ECT 6hr      97.30%         96.80%              97%             99%       97.90%         97.20% 
      
Tunel activity of the tumour cell lines at various timepoints after treatment  
 
Table 2.1:  Percentage of cells in vitro activity showing TUNEL activity as 
measured on the FACS. 
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2.4.3 Safety of EndoVe Application: Porcine Assessment 
The EndoVe was applied to intraluminal pig tissues to validate the efficacy and 
safety of the system. Tissues tested included the oesophagus and rectum/colon. Due 
to the absence of a suitable porcine gastrointestinal tumour model we tested the 
EndoVe device in twenty pigs to a) safely under vacuum pressure draw tissue into 
the chamber with increasing negative pressure from -100 to -800mmHg and b) treat 
tissue at a 1Hz frequency, eight 100sec pulses at a voltage of either 1000V/cm or 
1400V/cm and subsequently biopsied for H&E staining 48hrs post procedure (Figure 
2.3B). All 20 porcine cases were performed with no trauma, burns or perforations 
observed in the seven days post procedure follow up. 
 
2.4.4 EndoVe-delivered Electrochemotherapy of Spontaneous Canine 
Colorectal Tumours 
Two dogs with spontaneous, inoperable colorectal tumours were treated with 
EndoVe-delivered ECT. Both animals received intravenous (i.v.) Bleomycin and were 
treated under a short general anaesthesia.     
 
2.4.4.1 Case 1                                                                                                                                                                        
A 10 year old sheltie with rectal bleeding, diarrhoea and loss of condition, including 
significant recent weight loss was presented. Colonoscopy revealed an obstructing 
colorectal mass about 10 cm proximal from the anal verge (Figure 2.4A). 
Histopathologic analysis confirmed that this lesion was an adenocarcinoma. The 
tumour was deemed unsuitable for surgical resection and the dog was referred for 
ECT. The tumour was treated with two separate sessions of ECT on days 15 and 34. 
After each ECT session, the size of the mass was visibly decreased (Figure 2.4B and 
C). Complete regression was obtained after two ECT sessions (Figure 2.4D). No 
relapse was observed over two and a half years following the last treatment.  
Complete regression was confirmed by biopsies confirming the presence of no 
residual tumour tissue (Figure 2.5). 
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Figure 2.4: ECT of a canine rectal adenocarcinoma. (A) Endoscopic images of an 
obstructing tumour 10cm from the anal verge, (B) 15 days following the first session 
of ECT; (C) continuing tumour regression after a second session of ECT; (D) 
complete tumour regression following 2 sessions of ECT.  
A B 
C D 
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Figure 2.5: Haemotoxylin and Eosin staining demonstrating (A) canine colorectal 
adenocarcinoma pre-electrochemotherapy and (B) complete histologic regression 2 
years following electrochemotherapy 
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2.4.4.2 Case 2                                                                                                                                                                                
A five year old terrier presented with diarrhoea, weight loss and lethargy. 
Colonoscopy revealed a partial obstructing colonic mass of 6 cm in length from the 
anal verge (Figure 2.5A). Histopathologic analysis confirmed that this mass was a 
lymphoma. The tumour was referred for ECT. Complete regression was obtained 
after two ECT sessions (Figure 2.5 B and C). No relapse was observed two years 
post treatment (Figure 2.5D).  Tumour regression was also confirmed histologically 
(Figure 2.6). 
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Figure 2.5: ECT of a canine lymphoma. (A) Endoscopic images of a rectal tumour 
6cm from the anal verge, (B) 23 days after treatment with ECT, (C) 46 days after 
treatment with ECT, (D) 2 years following treatment.  
 
 
 
 
 
 
 
 
 
A B 
C D 
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Figure 2.6: Haemotoxylin and Eosin staining demonstrating (A) canine colorectal 
lymphoma pre-electrochemotherapy and (B) complete histologic regression 2 years 
following electrochemotherapy  
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2.5 Discussion 
Minimally invasive tumour ablation is a valuable clinical option in the cancer 
therapeutic armamentarium with electroporation presenting itself as a method with 
exciting potential clinical applications. The effectiveness of both reversible and 
irreversible electroporation in tumour ablation clinically has been reported by 
multiple investigators [3, 4, 12-14]. Clinical experience with reversible 
electroporation has been published extensively as a therapy that improves tissue 
permeability to specific chemotherapeutic agents providing local control of 
cutaneous cancers unsuitable for surgery and resistant to chemo/radiotherapy [15-
18]. Surrounding healthy tissue structures remain preserved after the procedure 
allowing wider margins around the tumour to be rapidly treated. Published 
experiences with ECT demonstrate that the non-thermal apoptotic type cytotoxic 
effects are confined to the region of tumour tissue covered by the electrical field. 
Because the dose of chemotherapy used for a single therapy, whether administered 
intralesionally or systemically, is usually less than one twentieth of the cumulative 
dose used in a standard systemic regimen, there are minimal systemic side effects 
[17-19].  
To date, the equipment for electroporation has not existed to allow for 
endoscopic delivery to gastrointestinal tissues. We have demonstrated that 
electroporation delivered with the EndoVe device in combination with Bleomycin 
can offer a potent targeted anticancer modality for gastrointestinal tumours while 
also generating a favourable immunological modulation occurring in the period post 
treatment.    
The EndoVe device (Figure 2.1Aand B) works in conjunction with routine 
endoscopic equipment where the device attaches over the distal end of the 
endoscope, without obscuring the lens. As such the device allows for both optimal 
manoeuvrability of the electrode system to the targeted tissue and for contact 
between the electrode system and the targeted tissue to be achieved. Incorporation of 
an external lip into the shape of two plate electrode contained within the device 
chamber allowed for the electrical field generated to permeate the tissue under the 
device not drawn into chamber under vacuum (Figure 2.1C). The transparent roof of 
the device chamber allows for tissue capture, and its subsequent release, to be 
visually confirmed (Figure 2.1B). Initial prototypes of the device have been made 
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from rigid materials making it more suitable for colorectal application. A flexible 
version is currently under development for oesophageal and gastric clinical 
applications.  
Employing previously optimized electroporation and chemotherapy 
parameters [8, 17] murine colorectal tumours were treated using electroporation 
delivered via a miniature EndoVe. Mice in the untreated, electroporation only and 
Bleomycin only groups were culled by day 12, whereas the combination treated 
tumours all showed excellent regression (CT26 10/10; CMT93 9/10) without 
recurrences (100 days). Cell death was rapid with TUNEL staining and FACS 
analysis on several gastrointestinal cell lines indicating over 90% of the cells 
undergoing apoptosis within six hours of treatment (Figure 2.3B and Table 2.1).  
We assessed the EndoVe device for safety and operation in a twenty pig 
study where the device was applied to ooesophageal, gastric and colorectal tissues. 
Tolerances for the vacuum (-50mmHg to -800mmHg) were assessed without 
obvious indications of trauma post procedure while simultaneously electroporation 
pulses were also deployed to the tissue over a voltage range of 500-1400V/cm.  
Technically electropermeabilisation occurs above 500V/cm and in our experience in 
the range up to 1200V/cm the procedure was completed smoothly, above which 
involuntary muscular contractions become an issue. The current delivered was in the 
range 8-12A per 100 sec pulse. Our calculations found that the total energy 
deployed to the tissue was approximately 25-60 joules per pulse and we 
demonstrated that the delivery of the electroporation pulse resulted in a change of 
less than 1C.   
Limitations in the design of the current device were encountered which 
related to its manoeuvrability, specifically difficulties were encountered in the 
porcine and canine models relating to manipulating the rigid device around the 
epiglottis which presented a challenge for the endoscopist. A revised design which is 
made of flexible material and shallower in depth should help overcome these 
difficulties. Placement and attachment onto a target pre-stained with india ink was 
achieved, with tissue traction easily achieved through the applied vacuum prior to 
delivery of the electroporation pulses.  
In the canine tumours treated the device was repositioned after each delivered 
pulse to ensure all of the tumour surface area received a minimum of one 
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application. The endoscopist worked from a mental map of a Venn diagram 
approach to ensure all of the target area was treated. Not all tumour tissue treated 
was amenable to being drawn into the EndoVe chamber although placement directly 
onto the surface alone was sufficient to ‘porate’ the underlying tumour. The 
procedures required an assistant to control the vacuum and electroporation generator 
while the endoscopist manipulated the device into position. Each step of placement, 
vacuum and delivery of pulse taking between 30-60 seconds, with the entire 
procedure completed in 10-20 minutes. No adverse events were noted, or signs of 
perforation in the treated tissues in any of the porcine and canine procedures, with 
complete tumour resolution observed in the two obstructive canine cases presented 
(Figures 2.4 and 2.5).  
Clinical application of endoscopic electroporation which is a non-thermal, 
targeted outpatient technology offers clinicians a new option for the treatment of 
gastrointestinal cancers. Electroporation may be clinically considered initially for the 
palliation of symptoms with local control of the tumour.  
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Chapter 3 
Enhancement of Electroporation-Facilitated  
Immunogene Therapy via Treg Depletion 
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3.1 Summary 
Regulatory T cells (Treg) can negatively impact tumour antigen-specific immune 
responses after infiltration into tumour tissue. However, depletion of Treg can 
facilitate enhanced anti-tumour responses, thus augmenting the potential for 
immunotherapies. Here we focus on treating a highly aggressive form of cancer 
using a murine melanoma model with a poor prognosis. We utilise a combination of 
Treg depletion and immunotherapy plasmid DNA delivered into the B16F10 
melanoma tumour model via electroporation. Plasmids encoding murine GM-CSF 
and human B71 were transfected with electroporation into the tumour and transient 
elimination of Treg was achieved with CD25 depleting antibodies (PC61). The 
combinational treatment effectively depleted Treg cells compared to the untreated 
tumour and significantly reduced lung metastases. The combination treatment was 
not effective in increasing the survival, but only effective in suppression of 
metastases. These results indicate the potential for combining Treg depletion with 
immunotherapy based gene electrotransfer to decrease systemic metastasis and 
potentially enhance survival. 
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3.2 Introduction 
Although malignant melanoma comprises less than 5% of malignant skin tumours; it 
is responsible for almost 60% of lethal skin neoplasms [1, 2]. The incidence of 
malignant melanoma continues to rise, while at the same time current treatment 
regimes show limited impact on survival [1, 2]. Existing treatment strategies include 
surgery, chemotherapy and radiotherapy, however many patients succumb to local 
regional and distal recurrences [3-5]. Current management of melanoma relies on 
primary prevention and early detection of disease [3, 6] and new treatment 
approaches that are more tolerable, reduce the risk of relapse and do not impinge on 
the patient’s quality of life are urgently required.  
                  Conventional therapies have demonstrated poor anti-cancer effects for 
reasons such as chemo-resistance and rapid metastasis [7-10]. Due to its inherent 
poor prognosis compounded by ineffective treatment regimens, there is a significant 
drive to design diverse treatment strategies against melanoma, with immunotherapy 
representing a key therapy focus [11].  
                 There are a number of reasons to support the theory that malignant 
melanoma is an immunogenic tumour. Firstly, melanoma tumours are typically 
infiltrated with lymphocytes and a lymphocyte-depleted tumour is typically 
associated with a poorer prognosis [12, 13]. Malignant melanoma is also more 
common in immune suppressed, or immune compromised patients [14]. 
Additionally, a small proportion of melanoma tumours undergo spontaneous 
regression which is postulated to be related to immune surveillance [15]. 
              The goal of immunotherapy is to increase overall anti-tumour immunity and 
thus represents a potent means for cancer treatment. However, a major obstacle to 
the success of immunotherapy is the presence of negative factors that inhibit the 
immune system such as regulatory T cells [16]. Regulatory T cells (Treg) have been 
implicated as one of the major suppressive mechanisms of anti-tumour immune 
responses. Increased levels of Treg in tumours are often associated with poor clinical 
outcome and tumour progression in various tumour entities [16]. In healthy immune 
homeostasis, Treg (a subset of T cells) play a crucial role in maintaining 
immunological unresponsiveness to self-antigens and in suppressing excessive 
immune responses that would otherwise be harmful to the host [17]. However, in the 
tumour environment, Treg-induced immune suppression poses a significant barrier to 
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anti-cancer responses targeted by immune-therapeutic strategies [17-19]. We, and 
other groups, have demonstrated that an increase or decrease in Treg cells has a 
direct influence on the effect of an immunotherapy approach [20]. Other studies have 
used different therapeutic approaches including IL-12 and IL-2 which has had 
significant therapeutic responses [21-23]. We have previously reported that an 
immunotherapy DNA plasmid encoding the cytokine GM-CSF (pGMCSF-B7.1), 
combined with pre-conditioned Treg depletion, was effective in the treatment of 
murine fibrosarcoma [24]. 
 
3.3 Study Aims 
To determine the efficacy of immunotherapy in aggressive malignant melanoma we 
electrically delivered a plasmid encoding GM-CSF, in combination with Treg 
depleting anti-CD25 to mice receiving the melanoma tumour cell line B16F10. Our 
results demonstrate that this combinational approach significantly reduced tumour 
volume and systemic lung metastases and significantly improved overall survival 
time and thus represents a promising therapeutic approach against melanoma.  
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3.4 Materials and Methods 
3.4.1 Plasmids  
The mammalian expression vector pMG was purchased from Invivogen (Cayla SAS, 
Toulouse, France). A version of this plasmid, designated pGT141, containing the 
murine GM-CSF and human B71 genes transcriptionally controlled from the hEF1-
HTLV and CMV promoters respectively was designed and cloning was performed 
on contract by Invivogen. Human B7-1 cDNA has been shown previously to 
function in a murine setting. The inserts were confirmed by sequencing. Plasmids 
were propagated in E coli strain Top10 and purified on endotoxin-free Qiagen-tip 
500 columns (Qiagen).  
3.4.2 Animals and tumour induction 
3.4.2.1 Ethics Statement 
All animal husbandry and experimental procedures were approved by the University 
College Cork Animal Experimentation Ethics Committee and carried out under 
licenses issued by the Department of Health, Ireland as directed by the Cruelty to 
Animals Act Ireland and EU Statutory Instructions. 
 
3.4.2.2 Mice 
Female C57BL/6 (6-8 weeks) mice were obtained from Harlan Laboratories 
(Oxfordshire, England). All in vivo experiments were approved by the ethics 
committee of University College Cork and carried out under licenses issued by the 
Department of Health, Ireland as directed by the Cruelty to Animals Act Ireland and 
EU Statutory Instructions. Mice were kept at a constant room temperature (22oC) 
with a natural day/night light cycle in a conventional animal colony. Standard 
laboratory food and water were provided ad libitum. The B16F10 cell line was 
obtained from the ATCC and cultured in DMEM supplemented with 10% v/v foetal 
calf serum, 300µg/ml L-glutamine. Tumour cells from a mid-log phase culture were 
harvested by brief exposure to 0.05% trypsin/EDTA solution, washed twice with 
PBS. For routine tumour induction, 5 x 105 tumour cells suspended in 200 µl of 
serum free DMEM were injected subcutaneously into the flank of mice. Following 
tumour establishment, tumours were allowed to grow and develop and were 
monitored by alternate day measurements in two dimensions using Vernier calipers. 
Tumour volume was calculated according to the formula V=ab2π/6, where a is the 
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longest diameter of the tumour and b is the longest diameter perpendicular to 
diameter a. From these volumes, tumour growth curves were constructed. Mice 
euthanized when the tumour diameter was between1.5cm.  
3.4.3 In vivo Treg cell depletion 
The anti-CD25 mAb (clone PC-61) was used to deplete and deactivate Treg in mice. 
Mice were treated with anti-CD25 mAb by i.p. injection in 0.25ml endonucleas-free 
PBS 1 day prior to performing experiments and every 4 days post tumour induction. 
Rat IgG1 (HRPN, anti-peroxidase horseradish) was used as a control (Bio-Express, 
NH). In previous studies the minimum dose required for each mAb was 1mgkg-1 
delivered intraperitonealy (i.p.) to achieve >95% reduction in systemic Treg cell 
numbers without non-specific T-cell activation [20]. Validation that the control Ab 
had no effect on Treg cell numbers was achieved using FACS. 
 
3.4.4 Flow cytometry analysis 
FACS analysis was performed using anti-mouse PE-foxp3, FITC-CD4 and APC-
CD25 and relevant isotype controls as per manufacturer (eBiosciences, Insight 
Biotechologies, UK). Single-cell suspensions from the spleens and tumours of 
individual mice were prepared to obtain a final concentration of 5 × 105 cells per 
well in blocking buffer (1× PBS/1% BSA/0.05% sodium azide/1% rat, hamster, and 
mouse serum). 50μl of each mAb dye and 5μl of the amine-reactive viability dye 
ViViD (Invitrogen) to determine dead cells was added to the blocking buffer. This 
was then incubated in the dark at 4°C for 30 min. Cells were washed twice with 
blocking buffer and finally re-suspended in 200μl 1% paraformaldehyde. To perform 
flow cytometric analyses and measure relative fluorescence intensities a FACS-Aria 
cytometer and BD Diva software (BD Biosciences) were used. For each mouse, 
20,000–200,000 events were recorded. The percentage of cells labelled with each 
mAb was calculated in comparison with cells stained with isotype control Ab. 
Background staining was controlled by labelled isotype controls (eBiosciences) and 
fluorescence-minus-one. The results represent the percentage of positively stained 
cells in the total cell population exceeding the background staining signal. For 
determination of intracellular foxp3 production, cells were then fixed and saponin 
permeabilised (Perm/fix solution, eBiosciences) and incubated with mAb or isotypic 
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control mAb. After 30 min cells were twice washed in permeabilisation buffer 
(eBiosciences) and then analysed by flow cytometry as described above. 
3.4.5 In vivo Electrogenetherapy 
When tumours reached approximately 100mm3 in volume (5-7mm major diameter), 
mice were randomly divided into experimental groups and subjected to specific 
experimental protocols. The procedure was carried out under general anaesthesia, by 
intraperitoneal (i.p.) administration of 200µg xylazine and 2mg ketamine. The skin 
overlying the flank tumour was shaved. Fifty µg of plasmid DNA in 50µl sterile 
injectable PBS was injected into the tumour. Two-needle array electrodes (Cork 
Cancer Research Centre, Cork, Ireland) were inserted on either side of the marked 
DNA injection point 80 seconds after DNA delivery for electroporation. The 
distance between the electrodes was 4mm. In vivo electroporation parameters were: 
1200V/cm 100µsec pulse length; 1 pulse and 120V/cm 20 msec; 8 pulses at 1 Hz 
were administered in sequence using the ePORE Gx (Cork Cancer Research Centre, 
Cork, Ireland) square wave generator. The high voltage pulse was used to induce 
electroporation in the cell membrane and the ensuing small voltage pulses were used 
to create an electrophoretic field to assist movement of the negative charged DNA 
plasmid across the cells.  
3.4.6 Statistical Analysis  
Experimental results were plotted and analysed for significance with Prism 4 
software (GraphPad software Inc, CA, USA). p< 0.05 was considered significant. 
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3.5 Results 
3.5.1 Suppression of primary tumour growth following administration of anti-
CD25 mAb 
Mice were injected intraperitonealy (i.p.) with anti-CD25 mAb (PC61) or rat IgG1 
one day prior to subcutaneous injection of B16F10 cells and every 4 days post 
tumour inoculation (Figure 3.1A) [25]. Subsequent monitoring of growth 
demonstrated that tumours grew significantly more slowly (p< 0.05) in the presence 
of anti-CD25 mAb when compared to untreated mice that had received no antibody 
or isotype control (IgG) (Figure 3.1B). Irrelevant rat IgG mAb when administered at 
an equivalent dose and time had no significant effect on growth or survival when 
compared with untreated tumours. Survival was improved significantly (p<0.02) 
when compared to the untreated group and the irrelevant antibody treated group from 
day 19 to day 24 (Figure3.1C). 
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Figure 3.1: (A) Experimental protocol. C57/BJ6 mice (n=6) were treated i.e. with 
anti-CD25 mAb, irrelevant IgG mAb or untreated 1 day prior to tumour inoculation 
and 4 days post tumour inoculation, 5 x 105 B16F10 cells were inoculated 
subcutaneously to the mice and tumour volume was monitored. (B) Tumour growth 
curves. Tumour growth from anti-CD25 mAb, irrelevant IgG mAb and untreated is 
presented as tumour volume measurements from day 0 to day 12. Tumour volume 
was calculated using the formula V=ab2/6. Data are presented as the means ± 
standard error of the mean. *At days 6, 8, 10 and 12, compared anti-CD25 mAb to 
untreated and IgG mAb, p<0.05. (C) Survival of tumour-bearing mice. Survival is 
presented using Kaplan-Meier survival curves. *Compared anti-CD25 mAb to 
untreated B16F10 and IgG mAb, p<0.02. 
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3.5.2 Immunogenetherapy Suppresses the Tumourigenicity of Murine 
Melanoma B16F10 Cells 
B16F10 mouse melanoma is considered a poorly immunogenic tumour (ATCC). 
C57BL/6 mice were challenged with 5 x 105 B16F10 cells subcutaneously and 
subsequently electroporated with pGMCSF-B7.1, pMG or untreated when tumours 
reached approximately 100mm3 in volume. Notably the immunogene group treated 
with pGMCSF-B7.1 showed significant reduction in tumour growth when compared 
to the untreated group (p<0.05), data presented (Figure 3.2A). This reduced tumour 
volume also correlated with significantly improved survival (p< 0.02), however the 
immunogenetherapy was not curative (Figure 3.2B). 
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Figure 3.2: (A) Tumour growth of pGT141 GM-CSF-B7.1, pMG and untreated of 
pre-established B16F10 tumour is presented from day 0 to day 12. Data are 
presented as the means ± standard error of the mean.  *At days 4, 6, 8, 10 and 12, 
compared pGMCSF-B7.1 to untreated B16F10 tumour, p<0.05. (B) Survival of 
immunogene treated tumour-bearing mice. Survival is presented using Kaplan-Meier 
survival curves. *Compared pGMCSF-B7.1 to untreated B16F10 tumour, p<0.02.    
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3.5.3 Combinational Therapy of anti-CD25 and Immunogene of B16F10 
Primary Tumour 
To determine how a combinational therapy approach might affect tumour growth we 
examined mice treated with a combination of immunogenetherapy and anti-CD25 
mAb. Mice received either anti-CD25 or rat IgG1, B16F10 cells and were then 
electroporated with pGMCSF-B7.1, pMG or untreated when tumours reached 
approximately 100mm3 in volume (Figure 3.3A). The pGMCSF-B7.1 and anti-CD25 
mAb combination treatment regime significantly reduced the growth of the tumour 
when compared to the untreated B16F10 tumour (p<0.05). There was no difference 
in growth rate when pGMCSF-B7.1 and anti-CD25 combination group was 
compared to pGMCSF-B7.1 and IgG group and pMG and anti-CD25 group (Figure 
3.3B). Importantly those mice receiving pGMCSF-B7.1 and anti-CD25 has 
significantly improved survival (p<0.05) compared to the untreated group (Figure 
3.3C). Overall, the combinational therapy approach had similar primary tumour 
outcomes when compared to either modality alone. There was no improved in the 
combination over the single and modality treatments.  
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Figure 3.3: (A) Protocol of antibody administration, immunogenetherapy and 
tumour inoculation. C57/BJ6 mice (n=6) were treated using the antibody regime 
previously described and combined with immunogene when tumour reached 
approximately 100mm3 in volume, 5 x 105 B16F10 cells were inoculated 
subcutaneously to the mice and tumour was monitored. (B) Tumour volume was 
measured and presented as means ± standard error of the mean. *Combinational 
treatment (pGMCSF-B7.1 and anti-CD25 mAb) compared to untreated B16F10, 
p<0.005. (C) Survival is presented using Kaplan-Meier survival curves. *Compared 
pGMCSF-B7.1/anti-CD25 mAb to untreated B16F10 tumour, p<0.02. 
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3.5.4 Suppression of Pulmonary Metastasis from B16F10 Tumour  
We next sought to examine how effective the pGMCSF-B7.1 and anti-CD25 
combination would be against metastatic disease. 24 days post primary tumour 
induction (Figure 3.4A), lungs were collected, weighed and photographed to 
determine the number of metastatic nodules on the lung surface (Figure 3.4B). In 
untreated mice with a primary B16F10 tumour we observed approximately 265 
metastatic nodules on the lung surface (Figure 3.4C). Mice in the single therapy 
groups (i.e. pGMCSF-B7.1 and IgG control or control pMG and anti-CD25) had 
significantly less metastatic nodules when compared to untreated or pMG and IgG 
combination (p<0.05). Notably only one mouse (out of 6) receiving the combination 
therapy (pGMCSF-B7.1 and anti-CD25) displayed any metastatic lung nodules and 
thus this group had significantly reduced (p<0.05) lung metastases when compared 
to single therapy or control groups.  
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Figure 3.4: (A) Schematic representation of treatment schedule: C57/BJ6 mice 
(n=6) were treated i.e. with anti-CD25 mAb, irrelevant IgG mAb or untreated 1 day 
prior to tumour inoculation and 4 days post tumour inoculation, 5 x 105 B16F10 cells 
were inoculated subcutaneously to the mice and tumour volume was monitored. 
Tumours were treated with ± pGMCSF-B7.1 or pMG when the tumours reached 
approximately 100mm3 in volume. (B) Macroscopic images of lungs (C) The 
number of surface metastases counted. The results represent those from 4 animals 
per group. (D) lung weight measurements are presented as means ± standard error of 
the mean. *pGMCSF-B7.1 and anti-CD25 mAb combinational treatment compared 
to pMG and anti-CD25, p<0.05. **pGMCSF-B7.1 and anti-CD25 mAb 
combinational treatment compared to pMG and IgG, p<0.05 
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3.5.5 T cell Changes During Treatment 
In order to assess the effect the therapy had on T-cells systemically and locally in the 
B16F10 tumour model, we collected tumour and spleens from anti-CD25 mAb, 
pGMCSF-B7.1 and the combination of pGMCSF-B7.1 and anti-CD25 mAb 
treatment groups. As expected, the anti-CD25 mAb treatment group significantly 
depleted the CD4+CD25+FoxP3+ cell population in both the tumour and spleen 
(Figure 3.5A-B). However there was no significant change in the 
CD4+CD25+FoxP3+ tumour cell population in the local pGMCSF-B7.1 treatment 
(Figure 3.5C). The combination treatment with pGMCSF-B7.1 and anti-CD25 mAb 
reduced both the CD4+CD25+FoxP3+ regulatory T cell and the CD4+CD25+FoxP3- T 
cell population (activated CD4+ T cells) (Figure 3.5D).  
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Figure 3.5: Anti-CD25 mAb i.p. administration inactivates Tregs locally and 
systemically at the tumour site and spleen. (A)  The CD4+CD25+FoxP3+ cell 
populations were significantly reduced. Compared anti-CD25 mAb to untreated 
B16F10 and IgG mAb in tumour p<0.004. (B) The CD4+CD25+FoxP3+ cell 
populations were significantly reduced. Compared anti-CD25 mAb to untreated 
B16F10 and IgG mAb in the spleen **p<0.001. (C) The immunotherapy with 
pGMCSF-B7.1 alone had no effect on the CD4+CD25+FoxP3 tumour cell 
populations. (D). Combinational treatment reduced the CD4+CD25+FoxP3+ cell 
population, (E) Combinational treatment also reduced the CD4+CD25+FoxP3- cell 
population compared to the untreated tumour *p<0.05. Data is presented as % 
respective cell population in the respective tissue ± standard error of the mean.  
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3.6 Discussion 
Malignant melanoma is one of the most aggressive forms of cancers and despite the 
development of molecular targeted therapies and improvements in surgery and 
radiotherapy many patients succumb to recurrences and secondary’s resulting in poor 
prognosis [9]. The absence of an effective immune response to metastatic melanoma 
is thought to contribute to this poor prognosis [11]. Several studies have described 
the presence and accumulation of Treg in tumours and their increase infiltrate to be 
associated to this overall poor prognosis. This accumulation increases with tumour 
volume and is coupled with the inhibition of innate immune rejection of the tumour 
and precludes the proliferation of effector cells [24-26]. Building on these 
observations we opted for a combinational regime of Treg depletion and an 
immunotherapy treatment.  
We choose an in-house plasmid encoding the cytokine GMCSF and the co-
stimulatory molecule human B7-1 which we previously demonstrated an effective 
recruitment of cytotoxic anti-tumour response and the permanent elimination of a 
poorly immunogenic fibrosarcoma tumour [20]. B7-1 is usually expressed on the 
membrane of antigen presenting cells (APC) whereas tumour cells usually lack its 
expression and without this costimulatory signal, T cells may become clonally 
anergic when the TCR signal is delivered. B7-1-transduced tumour cells are 
expected to present both the antigen (TCR receptor) and the costimulatory (CD28-
mediated) signals to CD8+ cytotoxic T lymphocytes (CTLs) simultaneously, leading 
to efficient activation of CTLs without requiring the assistance of CD4+ helper T 
cells [24]. The potential of immune based cancer treatments has been limited by 
negative immune-regulatory mechanisms, including tumour-derived factors that 
support cellular immunity and also host factors that suppress/inhibit cellular immune 
responses. Immune-suppressive CD4+CD25+FoxP3+ Treg accumulate in primary and 
metastatic cancers and can prevent treatment-induced immune responses therefore 
Treg depletion represents a promising therapeutic approach. Consistent with other 
studies we have shown that following anti-CD25 mAb administration, 
CD4+CD25+FoxP3+ regulatory T cells were depleted significantly (p<0.001) with a 
minimal but significant improved survival probably due to the reduction in the 
metastatic load. 
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Previously we have demonstrated an improved local response in a range of 
tumour types treated by electrogenetherapy with a DNA plasmid encoding for the 
GM-CSF and the humanB7.1 (pGMCSF-B7.1) [20, 24]. In keeping with this trend, 
the administration of the pGMCSF-B7.1 was associated with extended survival in the 
B16F10 primary tumour without being curative. This observation could potentially 
be due to the level of Treg cells accumulating in the tumour subsequently blocking 
any additional immune recruitment, even with an optimal expression of GMCSF-
B7.1. It is well documented that as a tumour grows the number of Treg cells also 
accumulates. Accumulations of Treg impinge on the effectiveness of any treatments 
and are associated with a negative clinical outcome. Thus, suppression of Treg so as 
to allow immune recruitment to the site of the tumour post pGMCSF-B7.1 
expression would be a distinct advantage to any treatment approach.  
We then decided to investigate the therapeutic potential of local pGMCSF-
B7.1 combined with systemic anti-CD25 mAb against established subcutaneous 
tumour and lung metastasis derived from the weakly immunogenic B16F10 
melanoma model. It was observed that there was a modest but significant 
improvement of primary tumour burden and survival observed for each of the 
individual treatments given alone or for the combinational treated groups. But the 
combinational therapy was not effective in halting the primary tumour.  The aim of 
all anti-cancer therapies is long-lasting responses that also prevent metastases and 
secondary tumours. The combination regime had a remarkable therapeutic efficacy 
of pre-existing lung metastases when compared to the use of either treatment alone 
indicating the suppression of Treg cells with the anti-CD25 when combined with the 
immunotherapy pGMCSF-B7.1 allowed for an enhanced anti-tumour CD8 immune 
response with the decrease in the levels of metastatic nodules.  
In conclusion, we have demonstrated that Treg depletion strategy combined 
with an immunotherapy was effective in our model. It was observed that the 
immunotherapy was only effective once the Treg cells were depleted. The 
combination of immumotherapy and Treg cell depletion resulted in an effective 
suppression of metastasis. We conclude the combined treatment was not effective in 
increasing the survival, but only effective in suppression of metastases. Although we 
were unable to stop the primary tumour this treatment could fit in as a debulking 
therapy prior to surgery and has the potential to treat the systemic and improving 
prognosis of metastatic melanoma patients. 
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4.1 Summary  
Despite advances in our understanding of the processes involved in the development 
and progression of cancer, treatment options for many patients are limited and 
prognosis still remains poor. Surgery followed by chemo- or radiation therapy has 
been the mainstay of treatment available for cancer patients. However, many cancers 
are resistant to these standard therapies. Non-viral plasmid DNA gene therapy 
represents a promising approach for the treatment of many diseases including cancer. 
Intracellular delivery of DNA can be achieved with the application of 
electroporation, facilitating the initial transport of exogenous DNA across the cell 
membrane into the cytoplasm. However, the variable rates of subsequent transport of 
DNA from the cytoplasm to the nucleus for mRNA expression has resulted in 
varying degrees of exogenous gene translation and proved a major limitation in 
comparison to viral approaches. To overcome these expression difficulties, we 
developed a proof of concept vector, the Enhanced Expression Vector (pEEV), 
incorporating elements from viral systems including nuclear localisation sequences 
and a viral replicase from the Semliki Forest Virus. The replicase allows for 
cytoplasmic mRNA expression and bypasses the need for nuclear localisation to 
generate high levels of gene expression. We have demonstrated that our ‘Enhanced 
Expression Vector’ – pEEV is capable of achieving high levels of expression in a 
variety of tissue types. The anti-tumour effects of pEEV were demonstrated by the 
delayed growth and increased survival of the non-therapeutic pEEV-treated CT26 
tumour model. Using a novel endoscopic electroporation system, EndoVe, we 
demonstrate and compare for the first time both standard CMV promoter-driven 
plasmid and pEEV gene expression in intraluminal porcine tissues. The pEEV 
plasmid displayed reliable and superior expression capability and, due to its inherent 
induced oncolytic activity in transfected cells, may enhance the efficacy and safety 
of several cancer immune-gene therapy approaches. 
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4.2 Introduction 
The field of cancer gene therapy is rapidly maturing and will no doubt be part of the 
future of cancer therapeutics. The critical questions are: Can any of these genes be 
used to induce cancer regression, increase sensitivity to conventional and biological 
anti-tumour treatments in cancer cells, or increase resistance of haematopoietic cells 
to cytotoxic agents? 
The principal challenge for gene therapy lies in the development of a method 
of transfection that successfully delivers a therapeutic gene to selected cells where 
gene expression can be achieved. The ideal gene delivery vector should fulfill three 
criteria: 1) it should protect the therapeutic gene against degradation by nucleases in 
intercellular matrices; 2) it should safely deliver the therapeutic gene across the 
plasma membrane and into the nucleus of target cells; and 3) it should not be 
associated with any detrimental effects.  
Clinical trials have thus far utilised two methods of gene delivery: viral and 
non-viral. Generally speaking, viral vectors offer an efficient means of gene 
transfection [168-171]. 
Despite the fact that viral vectors are able to mediate gene transfer with high 
efficiency and offer the possibility of long-term gene expression, they fail to fulfil 
the third criterion of the ideal gene therapy vector: safety [170, 172]. While retroviral 
vectors have the advantage of mediating stable gene transfer by integrating into the 
host genome and have a low potential for immunogenicity, this vector system has its 
limitations: 1) difficulties in producing high titres of retrovirus; 2) the fact that only 
actively dividing cells are capable of being infected; 3) the possibility of insertional 
mutagenesis [173-175].  
Non-viral approaches with plasmid DNA offer potential advantages for 
clinical application particularly as they offer a reduced risk profile and a simplified 
preparation process. DNA plasmid vectors allow for the transfer of significantly 
larger genetic material than is possible using a viral system, are less expensive to 
manufacture, are considered safe, non-toxic and less immunogenic than viral vectors, 
and allow for repeat dosing if required [172, 176-178]. However, plasmid DNA 
vectors can often have lower expression profiles than viruses and therefore lack 
potency in human clinical trials [179]. Ultimately, for efficacy in gene therapy, the 
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plasmid must reliably express the gene of interest at adequate levels in the target cell 
[178, 179].  
The technology of electroporation has been employed effectively in both 
preclinical and clinical settings for the delivery of plasmid DNA [126, 180, 181]. It 
has also been used to enable the uptake by passive diffusion of specific 
chemotherapeutic drugs, with very high reported anti-tumour efficacy and negligible 
side effects [181-184]. The process of electroporation involves the delivery of a 
microsecond pulse directly to the targeted tissue, which increases the local porosity 
of the tissue to macromolecules [39].  Electroporation has been established as a safe 
and effective method clinically with excellent responses observed in several cancer 
gene therapy studies. Therapies such as the electroporation delivery of plasmid DNA 
encoding for IL-12 and AMEP have advanced to clinical trials [185-188]. While 
electroporation facilitates the cytoplasmic absorption of plasmid DNA, it still lags 
behind viral methods for inducing a high degree of exogenous mRNA expression in 
the target cells. Therefore, it is important to establish and refine methods to improve 
electroporation based gene delivery for clinical use. Optimizing strategies include 
modulation of electric field strength and pulse duration to enhance plasmid delivery, 
alteration of the extracellular matrix with enzymatic and chemical methods and the 
introduction of reactive oxygen species (ROS) inhibitors to reduce plasmid DNA 
destruction by ROS generation post electroporation [189-193]. All have an impact on 
increased transfer and gene expression efficiency via electroporation. 
Viruses ensure expression of their genome within an infected cell by -
expressing a copy of their own replicase, which can transcribe copies of its viral 
genome within the cytoplasm. In general, the major concern for using virus as an 
expression vector is their infective nature, which involves biological risks [194]. 
However, the utilization of replication-deficient viral vectors such as Semliki Forest 
virus (SFV) avoids this problem while allowing rapid and high-level gene delivery 
[194]. The Semliki Forest virus is a positive-stranded RNA virus of the 
genus Alphavirus of the family Togaviridae [195, 196]. It is a relatively simple virus, 
encoding only nine functional proteins of unique sequence. The SFV replicon is a 
eukaryotic expression vector includes the cis-acting sequence for 5’ and 3’ ends of 
the virus genome and all the non-structural proteins (nsP), with the virus structural 
proteins replaced by the foreign gene [197, 198]. By utilising a DNA replicase copy 
from the Semliki Forest Virus and incorporating nuclear localisation sequences to 
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facilitate initial nuclear localization of the pEEV and replicase expression we have 
been able to overcome some of the drawbacks that have hindered the application of 
non-viral approaches to cancer gene therapy.  
 
4.3 Study Aim 
In this study we sought to deliver a non-viral vector system that has the potential for 
clinical application in electroporation based gene therapy. We report a proof of 
concept Enhanced Expression Vector (pEEV) which encompasses a viral replicase 
from the Semliki Forest Virus. We aimed to improve upon nuclear entry by the 
incorporation of a nuclear localization sequence. We demonstrated cytoplasmic 
expression of the vector. We also investigated the oncolytic capabilities of the pEEV. 
Furthermore we compared expression levels of the pEEV with standard available 
plasmids in murine and porcine animal models.  
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4.4 Materials and Methods 
4.4.1 Plasmids 
For plasmid transfection, a pCMV-lacz plasmid (Plasmid factory) was used encoding 
a β- galactosidase protein (LacZ) gene under the control of a cytomegalovirus 
(CMV) promoter (Figure 4.1D). The pEEV plasmid was created by incorporating a 
Semliki Forest virus DNA replicase sequence (kindly donated by Prof Greg Atkins, 
Virus Group, Department of Microbiology, School of Genetics and Microbiology, 
Trinity College Dublin). A nuclear localization sequence was also incorporated to 
allow for more efficient nuclear targeting of the pEEV (Figure 4.1B). The pMG 
plasmid was purchased from InvivoGen (Figure 4.1C). Plasmids were propagated in 
E coli strain Top10 and purified on endotoxin-free Qiagen-tip 500 columns (Qiagen).  
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Figure 4.1 Schematic representation of the four circular plasmids used during this 
study A. pEEV-lacZ: The EEV plasmid was created by incorporating a Semliki 
Forest virus DNA replicase sequence (Non structural proteins 1-4), A nuclear 
localization sequence (NLS) was also incorporated to allow for more efficient 
nuclear targeting, a 26S subgenomic promoter (26S), the entire SFV capsid gene; 
which functions as a self-cleaving translation enhancer, capsid (CAP) gene, the LacZ 
gene which encodes for the β-galactosidase gene, SV40pA, an Ori colE1 (Ori) and 
an ampicillin resistance cassette (AmpR). B. pEEV: This is the backbone of the 
plasmid. The EEV plasmid was created by incorporating a Semliki Forest virus DNA 
replicase sequence (Non structural proteins 1-4), A nuclear localization sequence 
(NLS) was also incorporated to allow for more efficient nuclear targeting, a 26S 
subgenomic promoter (26S), the entire SFV capsid gene; which functions as a self-
cleaving translation enhancer, capsid (CAP) gene, SV40pA, an Ori colE1 (Ori) and 
an ampicillin resistance cassette (AmpR). C. pMG: The pMG plasmid was 
purchased from InvivoGen. It incorporates the Human Elongation Factor-1α (EF-
1α)/Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat (HTLV) hybrid 
promoter (hEF1CCCa/HTLVp), a multicloning site (MCS), Simian virus 40 late 
polyadenylation signal (SV40pA). D. pCMV-lacZ: CMV promoter from pcDNA3, 
the LacZ gene which encodes for the β-galactosidase gene, SV40polyA, Ori and an 
AmpR. 
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4.4.2 Animal Studies  
4.4.2.1 Ethics Statement 
All animal husbandry and experimental procedures were approved by the University 
College Cork Animal Experimentation Ethics Committee and carried out under 
licenses issued by the Department of Health, Ireland as directed by the Cruelty to 
Animals Act Ireland and EU Statutory Instructions. 
 
4.4.2.2 Mice 
Female Balb/c, C57BL/6 and MF1-nu/nu mice (6-8 weeks) were obtained from 
Harlan Laboratories (Oxfordshire, England). All mice were kept in a conventional 
animal colony under standard conditions. Female mice in good condition, weighing 
16-22g and of 6-8 weeks of age were used in the experiments.  
 
4.4.2.3 Pigs  
Female Pigs (Landrace) were obtained from Teagasc, Moorepark, Ireland and used 
at 25-30 Kg. Standard laboratory food and water were provided ad libitum. Pigs 
scheduled for surgery were fasted from the night before. Prior to initiation of general 
anaesthesia, pigs were sedated with 400mg of Ketamine and 80mg of Xylazine 
injected into the cervical musculature. Once the pig was sedated (approximately 5 
minutes later), the skin overlying the flank and abdominal wall were shaved and 
thoroughly cleaned. A 22G cannula was inserted aseptically into a peripheral ear 
vein and flushed with normal saline to ensure correct positioning. 150mg/3ml of 
Amiodarone hydrochloride (a Class III anti-arrhythmic) was then administered 
intravenously (i.v.) as a cardioprotective agent. Anaesthesia was maintained using a 
200mg Ketamine and 10mg Midazolam. This combination of sedation followed by 
maintenance anaesthesia resulted in approximately 40 minutes of deep general 
anaesthesia.  
Prior to surgery, the level of anaesthesia was confirmed using the toe-pinch 
procedure. The porcine tissues accessed for study were the muscle, liver, spleen, 
ooesophagus and rectum.  
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4.4.3 Cell Tissue Culture  
Tumour cell lines were obtained from the American Type Cell Collection (Manassas, 
VA). The murine colon adenocarcinoma, CT26 cell line was cultured with 
Dulbecco's modified Eagle's media (DMEM; Sigma), supplemented with 10% v/v 
foetal calf serum and 300µg/ml L-glutamine. The human adenocarcinoma, OE19 cell 
line was cultured in RPMI-1640 (Sigma) supplemented with 10% v/v foetal calf 
serum and 300µg/ml L-glutamine. Cells were maintained in logarithmic phase 
growth at 37°C in a humidified atmosphere supplemented with 5% CO2.  
 
4.4.4 Tumour Induction 
For routine tumour induction, 1 x 106 CT26 or OE19 tumour cells, suspended in 200 
µl of serum free DMEM were injected subcutaneously into the flank Balb/C (CT26) 
or MF1-nu/nu mice (OE19). Tumours were allowed to develop and size was 
monitored by measurements in two dimensions using Vernier callipers. Tumour 
volume was calculated according to the formula V=ab2 /6, where a is the longest 
diameter of the tumour and b is the longest diameter perpendicular to diameter a. 
From these volumes, tumour growth curves were constructed. Mice were euthanized 
when tumour volume reached 1.7 cm3 as approved by the University College Cork 
Animal Experimentation Ethics Committee.  
 
4.4.5 DNA Transfection and In Vivo Electroporation  
A range of tissues were transfected including a subcutaneous tumour (OE19) and 
healthy tissue (muscle, liver and spleen). Tissues were injected with 50 µg of the 
respective plasmid and surgically removed 48 hours following in vivo transfection by 
electroporation. The number of plasmid DNA and LacZ expression was then 
determined. Procedures were carried out under general anesthesia, using 
intraperitoneal (i.p.) .administration of 200 µg xylazine and 2 mg ketamine. The skin 
overlying the flank muscle and tumour was shaved and a midline laparotomy was 
used to expose the liver and spleen. Fifty µg of plasmid DNA in 50 µl sterile 
injectable phosphate buffer saline was injected into the tumour, muscle, liver and 
spleen. Parallel plate electrodes [130], with an adjustable separation setting, were 
inserted on either side of the marked DNA injection point and electroporation pulses 
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delivered within one minute of DNA injection. For this study plate electrodes were 
fixed at 1 cm apart.  
Pigs scheduled for surgery were fasted from the night before. Prior to 
initiation of general anaesthesia, pigs were sedated with 400mg of Ketamine and 
80mg of Xylazine injected into the cervical musculature. Once the pig was sedated 
(approximately 5 minutes later), the skin overlying the flank and abdominal wall 
were shaved and thoroughly cleaned. A 22G cannula was inserted aseptically into a 
peripheral ear vein and flushed with normal saline to ensure correct positioning. 
150mg/3ml of Amiodarone hydrochloride (a Class III anti-arrhythmic) was then 
administered intravenously (i.v.) as a cardioprotective agent. Anaesthesia was 
maintained using a 200mg Ketamine and 10mg Midazolam. This combination of 
sedation followed by maintenance anaesthesia resulted in approximately 40 minutes 
of deep general anaesthesia. Prior to surgery, the level of anaesthesia was confirmed 
using the toe-pinch procedure. The porcine tissues accessed for study were the 
muscle, liver, spleen, ooesophagus and rectum.  
Surgical access to muscle tissue was obtained by making a 6 cm linear 
incision over the appropriate flank using monopolar diathermy (Figure 4.2). Open 
surgical access to the liver and spleen was obtained through a midline laparotomy 
incision (Figure 4.3A and 4.3B).  
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Figure 4.2 : (A) For surgical access to muscle, a 6cm linear incision was made using 
monopolar diathermy; (B) 50µg of plasmid DNA was injected intramuscularly 
(i.m.); (C) the EndoVe system of parallel plate electrodes was used to deliver the 
pulses; (D) Successful pulse generation was confirmed by the ePORE Gx (Cork 
Cancer Research Centre, Cork, Ireland). 
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Figure 4.3: (A) For open surgical access to the liver and spleen, a midline incision 
was made using monopolar diathermy; (B) the liver (pictured) or spleen was 
exposed; (C) 50g of plasmid DNA was injected; (D) the EndoVe system of parallel 
plate electrodes were used to deliver the pulses; (E) successful vacuum suction of the 
tissue into the electroporation chamber was confirmed by the indentation left on the 
surface of the organ; (F) Successful pulse generation was confirmed by the ePORE 
Gx (Cork Cancer Research Centre, Cork, Ireland)  
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Fifty µg of plasmid DNA in 50µl sterile injectable phosphate buffered saline 
was injected directly into the target tissues (Figure 2.3C). Access to the 
gastrointestinal tissues - ooesophagus and rectum was achieved using the EndoVe 
device (Cork Cancer Research Centre, Cork, Ireland) (Figure 2.3D). Electric pulses 
were delivered using the EndoVe. In-vivo electroporation parameters were: A single 
1200 V/cm 100 μsec pulses followed after one second by a train of 8, 120 V/cm 20 
msec pulses at 1 Hz administered in sequence using the ePORE Gx (Cork Cancer 
Research Centre, Cork, Ireland) electroporation generator (Figure 2.3F).  
 
4.4.6 Histologic Evaluation 
Animals were sacrificed; tissues extracted and washed three times in PBS. β-
galactosidase staining was performed on tissue using the β-galactosidase reporter 
gene staining kit (Sigma). Tissues were fixed in a 1X fixation solution for 30 min. 
After fixation, the tissues were rinsed three times in PBS and incubated for 24 h in 
X-gal staining solution. Tissues from each animal were processed separately. At the 
end of the incubation period, tissues were rinsed with PBS. Tissues were embedded 
in paraffin and serial sections were cut at 5 µm and mounted on slides. Heamatoxylin 
and Eosin staining was performed for both murine and porcine samples to assess for 
tissue damage.  
 
4.4.7 RNA Isolation and Reverse Transcriptase Reaction 
Frozen tissue samples preserved in RNAlater were homogenised in the presence of 
Trizol (Sigma) and total RNA was isolated according to manufacturer’s instructions. 
Each sample was treated with DNase I (Ambion) to eliminate any possible DNA 
contamination and subsequently tested for presence of DNA using PCR 
amplification without the reverse transcription (RT) step. Total RNA concentration 
was determined from spectrophotometric optical density measurement (260 and 280 
nm). For each sample tested, the ratio between the spectrophotometric readings at 
260 nm and 280 nm (OD260/OD280) was used to provide an estimate of the purity 
of the nucleic acid, and the ratio in all samples ranged between 1.7 and 2.0. Reverse 
transcriptase reactions were carried out using the omniscript® reverse transcription 
kit (Qiagen) and Oligo(dt)15 primer (Promega). Each reaction tube contained 1 µg of 
DNAse-treated total RNA in a volume of 20ul.  
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4.4.8 Genomic DNA Extraction  
Genomic DNA was prepared according to manufacturer’s protocol using the 
genEluteTM mammalian genomic DNA miniprep kit (Sigma-Aldrich). Final DNA 
concentration was determined with the use of spectrophotometric measurement.  
 
4.4.9 Real Time PCR (qPCR)  
RT-PCR amplification was performed with the lightCycler® fastStart DNA master 
SYBR green I (Roche) at final concentrations of 3mM magnesium, 0.5 µM of each 
primer and 1 X LightCycler® FastStart DNA master SYBR green I. The final volume 
of each reaction was 20µl, containing 50 ng of RT product as template. The 
amplification programme started with 1 cycle at 95°C for 10 min, followed by 38 
cycles at 95°C for 15 sec, 60°C for 20 sec and 72°C for 20 sec. The programme 
ended with 1 cycle at 72°C for 15 min. The following primers for lacZf and lacZr 
were designed to amplify 185-bp and their sequences are as follows  lacZf  5’-GCG 
TGG ATG AAG ACC AGC-3’, lacZr 5’-CGA AGC CGC CCT GTA AAC-3’. The 
housekeeping 18s rRNA was used as an internal control [199]. 18srRNAf 5’-TTG 
ACG GAA GGG CAC CAC CAG-3’, 18srRNAr 5’-GCA CCA CCA CCC ACG 
GAA TCG-3’. For genomic PCR all samples were normalized to 100 ng/ μl of 
gDNA. 100 ng of DNA was used with similar PCR mixture contents and cycling 
parameters (40 cycles). LacZgf 5’-GAC GTC TCG TTG CTG CAT AA-3’ LacZgr 
5’-CAG CAG CAG ACC ATT TTC AA-3’.  
 
4.4.10 Quantification of Apoptosis by TUNEL 
To assess whether pEEV vector could also induce apoptotic death in vivo, pEEV, 
pEEV lacZ and pCMV lacZ was delivered into CT26 tumours via electroporation. 
Evaluation of the tumours for terminal deoxynucleotidyl transferase-mediated 
deoxyuridine triphosphate nick-end labelling (TUNEL; Roche) staining (which 
marks apoptotic cells) was utilised. Balb/C mice bearing CT26 tumours were 
subcutaneously injected with 50 μg of plasmid DNA followed by electroporation. 
Mice were culled on 24, 48 and 72 hours post treatment and tumours were removed 
for detecting in situ apoptosis by TUNEL assay. The TUNEL-positive cells were 
stained brown. TUNEL staining of tissues was performed according to the 
manufacturer’s protocol with minor modifications. In brief, processed tissues were 
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embedded in paraffin, cut into 5 µm thick sections, placed on superfrost® plus slides 
and adhered by heating at 37°C for 12 hours. Slides were deparaffinized and 
rehydrated by successive incubations in xylene, absolute ethanol, and 70% ethanol. 
Nuclei in tissue sections were stripped of protein by treating with proteinase k 
(20µg/ml) for 20 min followed by four successive washes with phosphate buffered 
saline (PBS). Slides were incubated with TUNEL reaction mixture at 37°C for 60 
min in a humidified atmosphere followed by three successive washes with PBS. 
Sections were incubated with horse-radish peroxidise (Roche) for 30 min, rinsed in 
PBS and stained with DAB substrate kit (Dako) according to manufactures’ 
recommendations. A positive control was established by incubating tissue section 
with DNase (1µg/ml) after deproteination and peroxidase inactivation. Intense 
staining was observed in cells from the DNase treated sections. A negative control 
was established by incubating tissue sample with DAB after deproteination and 
peroxidase inactivation. No staining was observed. 
  
4.4.11 Bioluminescence Imaging  
 Bioluminescence imaging was performed as previously described (15), with an IVIS 
100 charge-coupled device imaging system (Xenogen, Alameda, CA). 
Bioluminescent signals were quantified by the creation of regions of interest (ROIs). 
To standardise the data, light emission from the same surface area (ROI) was 
quantified for each transfected animal. In addition, background light emission, taken 
from ROIs created on untransfected control animals, was subtracted from transfected 
test animals. Imaging data were analysed and quantified with Living Image Software 
2.50 (Xenogen) and expressed as photons/second/cm2. 
 
4.4.12 Cytoplasmic Expression Assay 
Cytoplasmic expression was assessed for both plasmid systems using a nuclear free 
cytoplasmic prep. The standard commercial rabbit reticulocyte lysate cell-free 
system (Promega) was used to characterise translation products from mRNA 
encoding T7 RNA polymerase. This preparation consisted of a cytoplasmic free of 
nuclear material lysate and mRNA encoding T7 RNA polymerase. Each plasmid was 
incubated at 30oC for a period of 2 hours. Luciferase expression was detected using 
the IVIS 100 charge-coupled device imaging system (Xenogen, Alameda, CA). 
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pCMV was added as a control plasmid to demonstrate the efficiency of pEEV 
expression in cytoplasm lystae when there is a mRNA encoding T7 RNA 
polymerase present and the requirement of the T7 promoter.  
 
4.4.13 Statistical analysis  
Experimental results were plotted and analysed for significance with Prism 4 
software (GraphPad software Inc, CA, USA). P < 0.05 was considered significant. 
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4.5 Results  
4.5.1 Construction of pEEV 
The pEEV construct consists of the CMV IE/T7 promoter and SV40 polyadenylation 
(pA) (Figure 4.4). It includes the entire SFV capsid gene, which functions as a self-
cleaving translation enhancer, an Ori colE1 (Ori) and capsid (CAP) gene. It also 
includes the SFV 1-4 non-structural components and an ampicillin resistance 
cassette. To this an expanded multiple cloning site (MCS) was incorporated for the 
inclusion of foreign transcripts. For our study, lacZ transcript was incorporated. A 
nuclear localisation sequence  (NLS): 
CACATAACGGGAGGGCCGGCGGTTACCAGGTCGACGGATATGACGGCAG
G was inserted to allow for better transport in the nucleus.  
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Figure 4.4: Schematic representation of the circular pEEV plasmid constructed for 
this study. The circular pEEV construct incorporates a CMV IE/T7 promoter, an 
SFV replicase (non-structural proteins 1-4), nuclear localisation sequence (NLS), the 
entire SFV capsid gene; which functions as a self-cleaving translation enhancer, an 
Ori colE1 (Ori), 26S subgenomic promoter, capsid (CAP) gene and an ampicillin 
resistance cassette (AmpR). 
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4.5.2 Comparison of pEEV-lacZ to Standard pCMV-lacZ 
The pEEV plasmid (15.462Kb) is approximately three times larger, than the standard 
pCMV plasmid (6.233Kb), which could impact on transfection efficacy and 
expression. To establish this, we compared the transfection efficiency in vivo of 
pEEV with the pCMV plasmid. In order to determine efficiency, copy numbers of 
each plasmid expressing the lacZ transgene delivered by electroporation was 
measured. Both plasmids were detected in all tissues tested. In general, there were 
significantly more (p<0.001) copies of pCMV than pEEV (Figure 4.5), with the 
spleen and tumour having highest plasmid transfection.  
To evaluate expression, qPCR was used to detect lacZ transgene expression 
as a reporter system (Figure 4.6).  
Transgene expression from the pEEV was significantly higher (p<0.0001), 
and on average 4 fold higher, than the respective pCMV plasmid. Taken together, 
these data indicate that high expression is achieved via an active vector, where, 
although present in fewer copies, pEEV allows an enhanced expression profile over 
the standard pCMV. 
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Figure 4.5: Bar graph showing absolute copy number of the lacZ transgene per ng of 
genomic DNA 2 days after electroporation obtained from MF1-nu/nu mouse tissue. 
All gDNA samples were normalised to 100ng of DNA prior to PCR. Each individual 
sample was analysed in triplicate for each qPCR. qPCR values are means ± standard 
error of the mean (SEM) of triplicate measurements. A comparison of pEEV (light 
grey bars) and pCMV (dark grey bars) samples were performed ***p<0.0001.  
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Figure 4.6: Bar graph presenting the relative expression of the lacZ mRNA 2 days 
after electroporation obtained from MF1-nu/nu mouse tissue. All qPCR data was 
normalised using 18S RNA as reference gene. Relative expression levels are plotted 
as means ± standard error of the mean (SEM) of triplicate measurements. pEEV 
(light grey bars) and pCMV (dark grey bars). pEEV lacZ expressed was significantly 
higher than pCMV lacZ ***p<0.0001. 
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4.5.3 Demonstration of Cytoplasmic Expression of Luciferase  
The process for transcription of exogenous DNA material requires its translocation 
from the cytoplasm to the nucleus. The transcribed mRNA is then transported out of 
the nucleus for protein synthesis. Given that pEEV contains its own replicase, 
translation of the PEEV reported gene could occur within the cytoplasm. To assess 
the functionality of pEEV in a cell free assay, we used the functional activity of 
mRNA encoding T7 RNA polymerase, combined with the luciferase reporter gene. 
Luciferase expression from two plasmid constructs, the standard pCMV plasmid and 
pEEV were compared (Figure 4.7). We could only detect pEEV driven luciferase 
expression during this assay. These data confirmed the ability of pEEV to self-
express within the cell cytoplasm.  
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Figure 4.7: Luciferase reporter assay to verify activity of plasmid in a nuclear free 
preparation. Relative luciferase expression (RLU) was used as an indicator of 
expression and values are plotted as means ± standard error of the mean (SEM) of 
triplicate measurements. Only pEEV luciferase expression was detected. 
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4.5.4 Cytolytic Activity of pEEV 
In our construction of pEEV, we utilized components of the SFV, we therefore 
hypothesized that the non-viral pEEV may delay tumour growth due to excessive 
gene expression inducing oncolytic activity, and leading to cell lysis of transfected 
cells. We transfected pEEV in an established tumour model to determine anti-tumour 
activity in vivo. In growing CT26 tumours pEEV lacZ, pEEV backbone, pCMV lacZ 
and pMG backbone were transfected by electroporation and growth and survival 
rates were examined and compared to its respective untreated CT26 tumour. The 
non-therapeutic bearing pEEV significantly (p<0.05) reduced tumour volume when 
compared to the untreated tumour (Figure 4.8).  
Furthermore, we also observed improved survival of animal’s transfected 
with non therapeutic pEEV. Interestingly, these collective data indicate that non-
therapeutic pEEV can improve survival rates, which may be due to the oncolytic 
effect of pEEV lacZ (Figure 4.9).  
To further demonstrate the oncolytic effect of non viral pEEV we transfected 
muscle of MF1-nu/nu mice and C57BL/6 with pCMV luciferase and pEEV 
luciferase (Figure 4.10).  
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Figure 4.8: Tumour growth curve of CT26 tumours treated with pCMV backbone, 
pCMV lacZ, pEEV backbone, pEEV lacZ and an untreated tumours growing on 
Balb/c mice (n = 6 per group) is presented as tumour diameter measured. Tumour 
volume was calculated as previously described. Data presented are means ± SEM of 
6 individual tumours. *Compared to the untreated group and pEEV lacZ, *p<0.05. 
 
 
 
 
 
 
 
 
120 
 
 
 
 
 
 
 
Figure 4.9: The respective survival curve of the CT26 treated tumours growing on 
Balb/c mice (n = 6 per group). The pEEV lacZ treated mice survived longer than any 
other group p<0.05 versus the untreated tumour. The pEEV lacZ group survived 4 
days longer than the pEEV backbone. 
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Figure 4.10: In vivo intramuscular (i.m.) plasmid delivery. In vivo muscle 
transfection by electroporation was demonstrated by luciferase activity, analyzed 
daly postintramuscular (i.m.) pCMVluc and pEEVluc, plasmid transfection via 
electroporation and subsequent gene expression was assessed using whole body 
imaging of luciferase expression. pCMV expression peaked day 2 in both 
C57BL/6J(C) and MF1-nu/nu mice (D) and pEEV peaked day 7 in both MF1-nu/nu 
(A)  and C57BL/6J mice (B). No detection of pEEVluc was detected by day 9. (D) 
Bioluminesence data plotted over time for pEEVluc treated MF1-nu/nu mice (●) 
pEEVluc C57BL/6J mice (■) pCMVluc treated MF1-nu/nu mice (▲) and pCMVluc 
C57BL/6J mice treated mice (▼). Data is plotted as means ± standard error of the 
mean (SEM) of triplicate measurements Bioluminescent imaging revealed peak 
luciferase expression for pCMV at day 2 and day 6 for pEEV. pEEV expression was 
no longer detected by day 9, whereas, pCMV expression continued to be detected at 
low levels up until day 100. This quenching in luciferase expression of pEEV, 
suggests cell lysis due to the oncolytic effect of pEEV lacZ 
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4.5.5 Quantification of Apoptosis  
To assess the ability of pEEV vector in induce apoptosis, we analysed in vivo 
electroporated CT26 tumours for TUNEL staining. TUNEL staining shown in 
(Figure 4.11) shows pEEV lacZ electroporation tumours were abundant in apoptotic 
nuclei, with double-strand DNA breaks, which are hallmarks of apoptosis. Notably, 
pCMV-treated tumours did not have any TUNEL staining (i.e. apoptosis). These 
data further confirm the oncolytic effect of pEEV.  
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Figure 4.11: Apoptotic dead was evaluated using TUNEL staining on CT26 tumour 
model grown on Balb/c mice. Tumours were removed from mice at various time 
points following treatment; paraffin embedded and stained sections were examined 
microscopically. TUNEL stained for evidence of apoptotic cells indicate significant 
apoptosis in the tumour treated with pEEV lacZ and pEEV backbone but not from 
untreated groups. 
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4.5.6 β-galactosidase expression in a large animal model  
Previous studies have indicated that DNA vaccines are often less effective in large 
animals when compared to responses induced in mice. Translation of plasmid 
expression into patients is essential for any therapeutic potential to be established. To 
determine if pEEV had this potential we tested the plasmid expression in a porcine 
model. To test transgene expression after electroporation, we examined LacZ 
transgene driven β-Galactosidase expression. Histological analyses of transfected 
tissues (Figure 4.12) demonstrated positive β-Galactosidase expression in all test 
tissues with all controls negative for β-Galactosidase expression. Importantly, the 
visual expression profile of pEEV lacZ was more abundant in comparison to the 
standard pCMV plasmid.  
We again utilized the LacZ as a reporter transgene to compare the amount of 
gene expression induced from plasmids after electroporation, and to determine if the 
transgene expression was consistent with β-Galactosidase staining (Figure 4.13).  
As observed in the mouse models, pEEV lacZ was expressed at a 
significantly higher level when compared to the standard pCMV lacZ. To investigate 
efficiency of transfection in our large animal model, we determined overall copy 
number (Figure 4.14).  
Whilst we observed that overall copy number was significantly lower for 
pEEV when compared to pCMV (similar to murine studies), we again observed that 
pEEV gave a significantly stronger expression profile when compared to pCMV. 
Taken together, these results demonstrate that pEEV can be used to effectively 
express exogenous genes within multiple tissues in a large animal model. 
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Figure 4.12: Representative image of β-galactosidase staining in porcine tissues. β-
Galactosidase expression significantly increased in pEEV lacZ in all tissues been 
examined. 
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Figure 4.13: Bar graph presenting the relative expression of the lacZ mRNA 2 days 
after electroporation. All qPCR data was normalised using 18S RNA as reference 
gene. Relative expression levels are plotted as means ± standard error of the mean 
(SEM) of triplicate measurements. pEEV (light grey bars) and pCMV (dark grey 
bars). pEEV lacZ expressed was significantly higher than pCMV lacZ. 
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Figure 4.14: Bar graph showing absolute copy number of the lacZ transgene per ng 
of genomic DNAs 2 days after electroporation. All gDNA samples were normalised 
to 100ng of DNA prior to PCR. Each individual sample was analysed in triplicate for 
each qPCR. qPCR values are means ± standard error of the mean (SEM) of triplicate 
measurements. A comparison of pEEV (light grey bars) and pCMV (dark grey bars) 
samples were performed. 
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4.6 Discussion  
The current study provides evidence for significant enhancements in the potential for 
non-viral DNA vector systems. Clinically non-viral-mediated transgene expression 
has received increased attention because it is a relatively safe, simple, and 
inexpensive compared to administration of viral vectors, which are associated with 
the induction of neutralizing antibodies and cytotoxicity [177, 194]. Electroporation 
is considered as a very useful tool for gene therapies and has received a lot of 
attention to development and improve in electrogene transfer protocols. Studies have 
included modulating the electric pulse, electrodes, extracellular matrix which has an 
effect on transfection efficiency and expression of the delivered gene  [140, 189, 
191, 192, 200]. Others have modulated the size of the plasmid being delivered and 
used plasmid types such as mini-circle-plasmid [201]. We have incorporated 
elements of a virus and nuclear localization sequence to allow for an enhanced 
expression of the gene of interest. 
We have shown that a DNA based enhanced expression vector (pEEV), has 
improved expression capabilities across a range of tissue histologies over standard 
non- viral DNA vectors. pEEV was developed utilizing the Semiliki Forest Virus 
replicase, which allows for high levels of cytoplasmic expression and thereby 
overcoming the requirement and rate limiting step for all plasmid copies to enter the 
nucleus in order for mRNA transcription to occur. In the present study we evaluated 
our pEEV construct and demonstrated its superior efficacy using reporter gene 
analysis while comparing findings to a standard plasmid. pEEV delivered via 
electroporation, led to rapid mRNA expression in cancer cells. This approach was 
also found to have several advantages specifically for cancer therapy including; 
greatly improved and consistent gene expression, eventual direct oncolytic effect 
(cellular exhaustion) from continued mRNA production, which obviates the risk of 
long term exogenous gene expression. 
The enhanced expression vector construct contains a DNA sequence 15Kb is 
size. There was initial concern that the large size of pEEV would impact negatively 
on its transfection efficacy after electroporation. Our data indicates that transfection 
levels for pEEV i.e. copies of plasmid DNA within the cell post electroporation, 
were indeed lower in comparison to the standard pCMV plasmid which was only 
6.2kB in size. However, previous studies have indicated that self-amplifying vectors 
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only need a single RNA copy to reach the cytoplasm, whereby they can generate 
high expression levels almost independent of initial transfection and transcription 
efficiency. Indeed, although we observed overall lower transfection rates of pEEV, 
when compared to the standard pCMV plasmid, this did not however result in a 
proportional decrease in mRNA expression levels within a nuclear free lysate. 
Significantly, mRNA expression levels were in fact 4-5 fold higher in pEEV 
transfected cells, when compared to the more efficiently transfected standard 
commercial pCMV. 
Targeting tumours with oncolytic viruses has demonstrated a promising 
approach for cancer treatment. These are modified or naturally oncotropic viruses, 
which selectively replicate in malignant tumour cells and finally destroy them via 
oncolysis but this approach also encounteres similar disadvantages as other viral 
therapies. Alphaviruses, like the Semliki Forest virus (SFV) have also been 
successfully used as oncolytic agents in several preclinical models of cancer. They 
are enveloped viruses containing a single positive strand RNA genome which, after, 
can replicate in the cytoplasm. The SFV system is suicidal and are characterised by 
their high expression levels. This process induces a strong cytopathic effect that 
leads to cell death by apoptosis. Taking these characteristics into account we 
incorporated these elements from the Semliki Forest Virus to develop the pEEV. We 
demonstrated cytoplasmic expression of pEEV and wanted to further characterise if 
pEEV had oncolytic effects like its viral parent. The stable presence and expression 
of plasmid DNA vectors in muscle have been demonstrated in several studies. We 
observed that in vivo muscle expression peaked on day 6 for pEEV transfection with 
expression levels declining and undetectable by day 9. This cellular oncolysis feature 
of pEEV could benefit cancer gene therapy applications such as by acting as a safety 
feature for over or continuous expression. Anti-tumour effects of pEEV were 
demonstrated by the delay in growth and increased survival of a non-therapeutic 
pEEV treated CT26 tumour model. This oncolytic characteristic and the high 
expression level trait of pEEV highlight the potential of this vector as an anti-cancer 
vector. 
The electroporation gene transfer protocol appears to be safe and non-toxic. 
All mice remained healthy throughout the course of the experiments and there were 
no treatment-related deaths. This suggests that electroporation of solid tumours is not 
traumatic and that the levels produced by the pEEV did not induce systemic toxicity. 
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Other studies have observed similar safe and non-toxic effects of electrogene transfer 
[163, 202]. The ultimate aim of any preclinical gene therapy study is to translate 
findings to the clinic. The safety of electroporation as part of treatment in human 
patients has been validated in several studies of electrochemotherapy and electrogene 
transfer [186, 203].  
We wanted to assess the of expression levels of pEEV, however efficacy in 
mouse models does not necessarily translate into patients. While our pEEV 
preclinical studies in mice revealed very promising results, we proceeded to validate 
the approach in the larger pig in vivo model. Pigs are an excellent larger animal 
model to study human physiology/disease due to many similar attributes including 
anatomy, genetics and physiology. Indeed, pig models have been used to evaluate 
the safety and efficacy of gene therapy; however studies have yielded varying results 
with regards to detectable levels of gene expression. Employing the EndoVe, a novel 
endoscopic electroporation device, we were able to demonstrate the reliability of the 
pEEV to express the b-galactosidase reporter gene across a range of intraluminal 
porcine tissue types. The high levels of pEEV reporter gene expression in this pig 
study indicates the potential utility of pEEV in the clinic and as a therapeutic tool in 
gene therapy. The data also clearly reveals the lack of consistent expression for the 
pCMV vector when translated from murine to porcine tissue, in contrast consistent 
levels of reporter gene expression were detected across all tissue types for the pEEV 
plasmid. 
A growing number of clinical studies have established that electroporation is 
safe and effective in delivering plasmid DNA and chemotherapeutic drugs efficiently 
[185, 186]. In this study we used a previously reported safe and nontoxic parameters 
of electroporation-mediated transfer of the DNA plasmid to deliver pEEV in vivo. 
We found that the combination of an already established electroporation 
methodology and pEEV allows for an extremely reliable means of gene delivery and 
expression.  
Taken together our results clearly demonstrate the potential of pEEV as a safe DNA 
vector with superior expression capabilities over standard available vectors. This 
vector, in combination with electroporation, allows for a safe and minimally invasive 
method of delivery. This study suggests that the pEEV expressing a therapeutic gene 
may have potential for clinical development with high detectable levels of 
expression. 
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Chapter 5 
Non-Viral Immune Electro-Gene Therapy Induces 
Potent Anti-Tumour Responses and has a Curative 
Effect in Murine Colon Adenocarcinoma and 
Melanoma Cancer Models 
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5.1 Summary 
Anti-tumour efficacy of electroporated pEEV plasmid, coding for granulocyte-
macrophage colony-stimulating factor and the B7-1 co-stimulatory immune 
molecule (pEEVGMCSF-B7.1) in growing solid tumours was investigated and 
compared to a standard plasmid. Application of pEEVGMCSF-B7.1 led to complete 
tumour regression in 66 % of CT26 treated tumours and 100 % in the B16F10 
treated tumours at day 150 post treatment. pEEVGMCSF-B7.1 treatment was found 
to significantly enhance levels of both innate and adaptive immune populations in 
tumour and systemic sites, which corresponded to significantly increased tissue 
levels of pro-inflammatory cytokines including IFN-γ and IL-12. In contrast 
pEEVGMCSF-B7.1 treatment significantly reduced T regulatory populations and 
also the anti-inflammatory cytokine IL-10. Upon further characterisation of 
functional immune responses we observed a significant increase in cytotoxic 
(CD107a+) and IFN-γ-producing NK cells and also significantly more IL-12 
producing B cells. Importantly, splenocytes isolated from pEEVGMCSF-B7.1 
treated ‘cured’ mice were tumour-specific and afforded significant protection in a 
tumour re-challenge model (Winn assay). Our data indicate that electro-immunogene 
therapy with the non-viral pEEVGMCSF-B7.1 is able to induce potent and durable 
anti-tumour immune responses that significantly reduce primary and also secondary 
tumour growth and thus represents a solid therapeutic platform for future clinical 
trials. 
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5.2 Introduction        
The current standard of care for cancer utilises surgery, radiation and chemotherapy, 
to achieve local tumour control and reduce the risk of disease recurrence [1].  
Immunotherapy is potentially a new therapeutic pillar which can complement the 
current standard of care and can reduce risk of disease recurrence [2-4]. 
Immunotherapy based therapies have the potential to activate a tumour 
antigen specific response which can help to eradicate the tumour and reduce the risk 
of disease recurrence [5-8]. Delivering immunotherapies clinically can be achieved 
through a number of approaches including the use of gene therapy, which has many 
applications and methodologies already developed for cancer treatment [9-12]. For 
gene therapy to be successful, safe and efficient gene delivery is critical [11]. In 
current cancer gene therapy studies, viral vectors are used in the majority of gene 
delivery approaches, as they have high efficiency transduction [13, 14]. However, 
there are a number of significant drawbacks which include; efficiency of production, 
host immunogenicity, integration and safety [14, 15]. An alternative option to viral 
vectors is plasmid DNA. Toxicity is generally very low, and large-scale production 
is relatively easy [16]. However, a major obstacle that has prevented the widespread 
application of plasmid DNA is its relative inefficiency in gene [16, 17]. Therefore, 
most applications for plasmid DNA have been limited to vaccine studies, with a few 
exceptions [17, 18]. Consequently, methods that can significantly increase plasmid 
DNA transduction efficiency will greatly extend the utility of this promising mode of 
gene transfer. The technique of electroporation is widely used in vitro to effectively 
introduce DNA and other molecules into eukaryotic cells and bacteria. Application 
of short electrical pulses to the target cells permeabilises the cell membrane, thereby 
facilitating DNA uptake [19]. A number of studies, preclinical and clinical have 
shown highly successful responses with electroporated plasmid DNA encoding 
immune genes and also chemotherapeutic drugs [20-24].  Recently, we have shown 
that that applying electroporation to a range of tissue types utilising a new 
electroporation system, EndoVe in a large pig model. This will significantly enhance 
the application of electro-gene therapy [25].    
Several cytokines have demonstrated significant anti-tumour effects. Among 
these, Granulocyte-macrophage colony-stimulating factor (GMCSF) is one of the 
most potent, specific and long-lasting inducers of anti-tumour immunity. GMCSF 
can mediate its effect by stimulating the differentiation and activation of dendritic 
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cells (DCs) and macrophages, increasing antigen presentation capability [26]. For 
optimal antigen presentation, engagement of the T-cell receptor (TCR) with an 
antigen/major histocompatibility complex requires the costimulatory molecule such 
as B7-1 (CD80) and B7-2 (CD86) [26, 27]. Subsequently, DC and macrophages, 
process and present tumour antigens to T cells, both CD4+ and cytotoxic (CD8+) T 
cells, augmenting the anti-tumour response [27]. As such, GMCSF is particularly 
effective in generating systemic immunity against a number of poorly immunogenic 
tumours [26].  
 
5.3 Study Aim 
We recently characterised a non-viral vector therapy system; pEEV with a vastly 
superior expression capacity when compared to a standard control vector. We 
present here the use of pEEV as a gene therapy vector carrying murine GMCSF and 
human b7-1 genes (pEEVGMCSF-B7.1). We used electroporation as a means to 
facilitate the delivery of the EEV plasmid and assessed the efficacy and immune 
induction in primary and secondary responses to treatment in murine colon 
adenocarcinoma and melanoma cancer models.   
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5.4 Materials and Methods  
5.4.1 Cell Tissue Culture 
 Tumour cell lines B16F10, CT26, LLC and 4T1 were obtained from the American 
Type Cell Collection (Manassas, VA). The murine colon adenocarcinoma, CT26 and 
lewis lung carcinoma, LLC cell line was cultured with Dulbecco's modified Eagle's 
media (Sigma) supplemented with 10% v/v foetal calf serum, 300µg/ml L-
glutamine. The human adenocarcinoma, 4T1 cell line and the mouse melanoma cell 
line was cultured in RPMI-1640 (Sigma) supplemented with 10% v/v foetal calf 
serum and 300µg/ml L-glutamine. Cells were maintained in logarithmic phase 
growth at 37°C in a humidified atmosphere supplemented with 5% CO2.  
 
5.4.2 Ethics Statement 
All murine husbandry and experimental procedures were approved by the University 
College Cork Animal Experimentation Ethics Committee and carried out under 
licenses issued by the Department of Health, Ireland as directed by the Cruelty to 
Animals Act Ireland and EU Statutory Instructions. 
 
5.4.3 Animals and Tumour Induction 
Female Balb/c, MF1-nu/nu and C57BL/6J (6-8 weeks) were obtained from Harlan 
Laboratories (Oxfordshire, England). All mice were kept in a conventional animal 
colony under standard conditions. Female mice in good condition, weighing 16-22g 
and of 6-8 weeks of age were used in the experiments. For routine tumour induction, 
5 x 105 tumour cells suspended in 200µl of serum free DMEM were injected 
subcutaneously into the flank of the female C57BL/6J, Balb/C or MF1-nu/nu mice. 
Following tumour establishment, tumours were allowed to grow and develop and 
were monitored by alternate day measurements in two dimensions using Vernier 
callipers. Tumour volume was calculated according to the formula V=ab2 /6, where 
a is the longest diameter of the tumour and b is the longest diameter perpendicular to 
diameter a. From these volumes, tumour growth curves were constructed. Mice 
euthanized when tumour diameter was between 1.7cm3.  
 
140 
 
5.4.4 Plasmids 
The pMG plasmid was purchased from InvivoGen. A version of this plasmid, 
designated pGT141, containing the murine GMCSF and human B7-1 genes 
transcriptionally controlled from the hEF1-HTLV and CMV promoters respectively 
was designed and cloning was performed on contract by Invivogen. The EEV 
plasmid was created by incorporating a Semliki Forest virus DNA replicase 
sequence (kindly donated by Prof Greg Atkins, Virus Group, Department of 
Microbiology, School of Genetics and Microbiology, Trinity College Dublin). A 
nuclear localization sequence was also incorporated to allow for nuclear targeting. 
The murine GMCSF and human B7.1 genes was also incorporated into the pEEV.  
Plasmids were propagated in E coli strain Top10 and purified on endotoxin-free 
Qiagen-tip 500 columns (Qiagen) The four plasmids used in the course of this study 
are demonstrated in (Figure 5.1). 
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Figure 5.1: Schematic representation of the four circular plasmids used during this 
study (A) pEEV: This is the backbone of the plasmid. The EEV plasmid was created 
by incorporating a Semliki Forest virus DNA replicase sequence (Non-structural 
proteins 1-4), A nuclear localization sequence (NLS) was also incorporated to allow 
for more efficient nuclear targeting, a 26S subgenomic promoter (26S), the entire 
SFV capsid gene; which functions as a self-cleaving translation enhancer, capsid 
(CAP) gene, SV40pA, an Ori colE1 (Ori) and an ampicillin resistance cassette 
(AmpR). (B) pEEVGMCSF-B7.1: The EEV plasmid was created by incorporating a 
Semliki Forest virus DNA replicase sequence (Non-structural proteins 1-4), A 
nuclear localization sequence (NLS) was also incorporated to allow for more 
efficient nuclear targeting, a 26S subgenomic promoter (26S), the entire SFV capsid 
gene; which functions as a self-cleaving translation enhancer, capsid (CAP) gene, 
GMCSF-IRES-B7.1; coding for granulocyte-macrophage colony stimulating factor-
internal ribosome entry site- B7.1 co-stimulatory immune molecule, SV40pA, an Ori 
colE1 (Ori) and an ampicillin resistance cassette (AmpR). (C) pMG: The pMG 
plasmid was purchased from InvivoGen. It incorporates the Human Elongation 
Factor-1α (EF-1α)/Human T-Cell Leukemia Virus Type 1 Long Terminal Repeat 
(HTLV) hybrid promoter (hEF1CCCa/HTLVp), a multicloning site (MCS), Simian 
virus 40 late polyadenylation signal (SV40pA). (D) pGT141GMCSF-B7.1: The 
pGT141GMCSF-B7.1 was purchased from InvivoGen. It incorporates the 
HEF1CCCa/HTLVp promoter, GMCSF, SV40, Ori, human CMV-IA promoter, 
SpAn, Intron A, B7.1, ECM IRES, hygromycin resistance cassette (HygroR). The 
GMCSF and B7.1 transcriptionally controlled from the HEF1CCCa/HTLVp and 
CMV-IA promoters respectively. 
142 
 
5.4.5 DNA Transfection and In Vivo Electroporation 
 Electroporation procedure was carried out under general anaesthesia, by 
intraperitoneal administration of 200µg xylazine and 2mg ketamine. Fifty µg of 
plasmid DNA in 50µl sterile injectable PBS was injected into the tumour followed 
by electroporation. In vivo electroporation parameters were: 1200 V/cm 100 µsec 
pulse length; 1 pulse and 120V/cm 20 msec; 8 pulses at 1 Hz were administered in 
sequence using the ePORE Gx (Cork Cancer Research Centre, Cork, Ireland) square 
wave generator. The high voltage pulse was used to induce electroporation in the cell 
membrane and the ensuing small voltage pulses were used to create an 
electrophoretic field to assist movement of the negative charged DNA plasmid 
across the cells.  
 
5.4.6 Flow Cytometry Analysis 
 Single cell suspensions from spleens and tumours of individual mice were prepared. 
Cells were added at a concentration of 2 x 105 cells/well (96-well plate) in blocking 
buffer (1 x PBS/1% BSA/0.05% sodium azide/1% rat, hamster and mouse serum). 
To this; 50µL of each mAb dye mix was added plus 5µL of amine-reactive viability 
UV dye (Invitrogen) to determine dead cells, with incubation in the dark at 4oC for 
30 min [28]. The mAb used for flow cytometry are listed in Table 5.1.  
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Table 5.1: FACS antibody list used in study. 
 
 
 
Target Molecule    Clone                     Isotype                   Conjugate               Source 
CD19 
CD49b 
CD3 
CD11c 
F4/80 
CD4 
CD8 
CD25 
FoxP3 
CD107a 
IFN-γ 
IL-10 
IL-12 
1D3 
DX5 
500A2 
N418 
BM8 
GK1.5 
53-6.7 
PC61.5 
FJK-16s 
1D4B 
MG-1.2 
JES5-16E3 
C17.8 
IgG2A 
IgM 
IgG 
IgG 
IgG2a 
IgG2b 
IgG2a 
IgG1 
IgG2a 
IgG2a 
IgG1 
IgG2b 
IgG2a 
Alexa Fluor 700 
FITC 
Alexa Fluor 700 
FITC 
PE-Cy7 
FITC 
PE-Cy7 
PerCP-Cy5.5 
Alexa Fluor 700 
Alexa Fluor 488 
APC 
APC 
PE 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
eBiosciences 
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Cells were washed and re-suspended in 200µL 3% formalin. To perform flow 
cytometric analyses a FACSLSRII 5 Laser (UV/Violet/Blue/Yellow-Green/Red) 
cytometer and BD Diva software (Becton Dickinson) were used. For each sample 
50,000-200,000 events were recorded. Background staining was controlled by 
labelled isotype controls and fluorescence-minus-one. The results represent the 
percentage of positively stained cells in the total cell population exceeding the 
background staining signal. For determination of intracellular cytokine production by 
leukocytes, cells were incubated for 6 h at 37°C with BD Activation Cocktail plus 
GolgiPlug (PMA, Ionomycin and brefeldin A [BD Biosciences]); unstimulated 
controls were also set up for each cytokine study. Cells were then washed with 
staining buffer and stained at 4oC for 30 min with appropriate surface mAb. Controls 
were stained with appropriate isotype-matched controls mAb. Cells were then fixed 
and saponin-permeabilised (Perm/fix solution, BD Biosciences) and incubated with 
mAb listed in Table S1 or isotype control mAb. After 30 min cells were twice 
washed in permealisation buffer (BD Biosciences) and then analysed by flow 
cytometry as described above. NK cells were identified as DX5+/CD3-, neutrophils 
as Ly6G+, DC as CD11c+, macrophages as F4/80+, B cells as CD19+ and T cell as 
CD4+ and cytotoxic T cells as CD8+.  
 
5.4.7 Analysis of Cytokine Levels 
Tumour and spleen homogenates were analysed using mouse pro-inflammatory 7-
plex (IFN-γ, IL-1β, IL-6, IL-10, IL-12p70, KC/GRO/CINC, TNF-α; Meso Scale 
Discovery). All assays were performed per manufacturers’ instructions. Cytokine 
levels are expressed as pg cytokine/ml (sensitivities of assays > 0.5-11pg/mL). 
 
5.4.8 Evaluation of Antigen Specificity and Long-Term Tumour Protection 
To test recall anti-tumour responses, naive and cured mice (primary B16F10 or 
CT26 tumour long-term; > 100 days) were rechallenged with the same tumourogenic 
dose of B16F10 or CT26 in the opposite flank and survival monitored over 100 days. 
Specifically, no further treatment was delivered following rechallenge. To assess the 
specificity of the pEEVGMCSF-B7.1 treatment was restricted to B16F10 or CT26 
cells mice bearing two different tumour types, including lewis lung carcinoma and 
4T1, were also assessed.  
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5.4.9 In Vitro Augmentation of Cytotoxic Activity 
To assay cytotoxicity activity against CT26 and B16F10 tumour cells mixed 
splenocytes were harvested from mice responding to GMCSF-B7.1 treatment and 
resistant to tumour growth on rechallenge with B16F10 or CT26. The spleen was 
harvested and tumour-specific lymphocytes induced by incubating, 2 x106 
splenocytes with 2 x105 mitomycin C-treated tumour cells in the presence of 25 
IU/ml rmIL2 (sigma) for 5 days. Lymphoid cells were then harvested, washed three 
times in serum-free medium and applied as effectors at various effector: target ratios 
(100:1, 50:1, 1:1) with 2 x104 target cells. 50:1 ratio had optimum effects and 
therefore data is shown. Cells were incubated overnight in 96-well plates to allow 
target cell killing. Wells were then washed five times with PBS to eliminate non-
adherent (dead and all effector cells). The MTT assay was used to quantify 
remaining living cells. MTT working solution (0.45mg/ml) was added to each well 
and cultures were incubated for 4 h at 37oC. Culture medium was then removed from 
each well and the precipitate dissolved with 150ml of dimethyl sulfoxide (Sigma) for 
10 min. Absorbance was read at 570nm and the percentage cytotoxicity was 
calculated. 
 
5.4.10 Statistical Analysis  
Experimental results were plotted and analysed for significance with Prism 4 
software (GraphPad software Inc, CA, USA). p<0.05 was considered significant. 
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5.5 Results  
5.5.1 Electroporation of pEEVGMCSF-B7.1 Results in Long-Term Inhibition of 
Tumour Growth in CT26 Murine Colorectal and B16F10 Metastatic Melanoma 
Models 
In the current study, we investigated the therapeutic efficacy of pEEVGMCSF-B7.1 
when compared to a standard vector also expressing GMCSF-B7.1. To test this, two 
tumour types (CT26 murine colorectal and B16F10 metastatic melanoma) were 
treated by electroporating tumours with pMG (standard plasmid backbone), 
pGT141GMCSF-B7.1 (standard plasmid therapy), pEEV (backbone) and 
pEEVGMCSF-B7.1 (Figure 5.2).  
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Figure 5.2: Therapeutic effect on established CT26 and B16F10 solid tumours. (A)  
Representative CT26 tumour growth curve:  Each Balb/C mouse was subcutaneously 
injected with 1 x106 CT26 cells in the flank. On day 14 post tumour inoculation, 
tumours were treated with pMG (■), pGT141GMCSF-B7.1 (▲), pEEV (▼) and 
pEEVGMCSF-B7.1 (♦) or untreated (●). 6 mice/groups were used and the 
experiment was performed twice. Tumour volume was calculated using the formula 
V=ab2/6. Data is presented as the means ± standard error of the mean. It was 
observed the pEEVGMCSF-B7.1 therapy delayed the growth of the tumours most 
effectively in comparison to the other groups. 17 days post treatment pEEVGMCSF-
B7.1 significantly delayed tumour growth compared to untreated tumour 
(***p<0.0004) standard therapy vector pGT141GMCSF-B7.1 ** p<0.002. (B) 
Representative Kaplan-Meier survival curve of CT26 treated tumours was measured. 
Only mice treated with pEEVGMCSF-B7.1 survived. 66% of mice survived up to 
150 days. All other groups were sacrificed by day 36 (C) Representative growth 
curve of B16F10 tumour. Each C57BL/6J was subcutaneously injected with 2 x105 
B16F10 cells in the flank of the mice. On day 15 post tumour inoculation, tumours 
were treated with pMG (■), pGT141GMCSF-B7.1 (▲), pEEV (▼) and 
pEEVGMCSF-B7.1 (♦) or untreated (●), 6 mice/groups were used and the 
experiment was performed twice. 12 days post treatment pEEVGMCSF-B7.1 
significantly delayed tumour growth compared to untreated tumour (**p<0.0001) 
standard therapy vector pGT141GMCSF-B7.1 (*p<0.0001). (D) Representative 
Kaplan-Meier survival curve of B16F10 showing pEEVGMCSF-B7.1 had 100% 
survival up to 150 days post treatment with all other groups sacrificed by day 28. 
Similar results were obtained in two independent experiments.  
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As expected the volumes of all non-electroporated (untreated) CT26 tumours 
and those treated with the empty plasmids, pMG and pEEV significantly increased 
(p<0.01) in size (Figure 5.2A). However, we did observe that the empty pEEV 
plasmid inhibited growth of the CT26 tumour between days 8-12, which we have 
observed previously [25]. Both therapeutic plasmids delayed the growth rate of the 
CT26 tumour. Importantly, the growth of pEEVGMCSF-B7.1 treated tumours was 
significantly more inhibited compared to pGT141GMCSF-B7.1 treated tumours 
(P<0.002) and untreated control tumours (p<0.0004). By day 26 post treatment, the 
untreated, pMG and pEEV treated groups were euthanized due to tumour size 
(Figure 5.2B). While the standard therapy pGT141GMCSF-B7.1 did inhibit tumour 
growth, all animals from this group were sacrificed by day 36 when the tumours 
reached the ethical size of 1.7cm3. One mouse was removed from the pEEVGMCSF-
B7.1 treated group on day 36 and again at day 45 due to tumours exceeding ethical 
size, however the remaining 66% survived up until day 150 post treatment when they 
were then sacrificed for subsequent immune analysis. To further test the efficacy of 
pEEVGMCSF-B7.1 therapy we utilised the B16F10 melanoma cell line due to its 
aggressive nature. Following the same experimental protocol as described for the 
CT26 model (Figure 5.2C) we again observed that untreated tumours grew 
exponentially with sacrifice from day 12 onwards (due to tumour size). Again we 
observed that pEEVGMCSF-B7.1 treatment delayed tumour growth when compared 
to the untreated group (p<0.0001) and pGT141GMCSF-B7.1 (p<0.0001). In terms of 
survival, the pMG, pEEV, untreated and pGT141GMCSF-B7.1 treated groups were 
sacrificed by day 28 (Figure 5.2D). Notably, we observed an even greater survival 
efficacy for the pEEVGMCSF-B7.1 (when compared to the CT26 model) in that 100 
% mice survived and all remained tumour free for 150 days post treatment until they 
were removed for subsequent immune analysis. Similar results were obtained in both 
tumour types treated in a range of tumour sizes (approximately 100mm3 to 350mm3). 
Taken together, these data indicate that pEEVGMCSF-B7.1 treatment is able to 
significantly reduced (in the CT26 model) or prevent (B16F10 model) primary 
tumour growth.  
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5.5.2 Treatment with pEEVGMCSF-B7.1 Results in Robust Cellular Immune 
Recruitment in Systemic and Local Tumour Sites 
As already indicated, for optimal cancer therapy, robust immune responses must be 
induced. Thus, to determine immune cell recruitment, we performed a 
comprehensive immune population profile of spleens and tumours 72 hour post 
treatment. CT26 tumour mice treated with pEEVGMCSF-B7.1 had a significantly 
greater percentage of splenic CD19+ (B cells), DX5+/CD3+ (NKT cells), DX5+/CD3- 
(NK cells) and CD8+ (cytotoxic T cells) as shown in Table 5.2. Within the tumour 
environment we observed that the percentage of all cell types examined (with the 
exception of CD4+ cells [T cells]) were significantly greater in pEEVGMCSF-B7.1 
treated tumours when compared to untreated tumours. Importantly, when the 
therapeutic plasmid treatments were compared we observed that pEEVGMCSF-B7.1 
treated mice had significantly more splenic and tumour CD19+ cells (P<0.05) and 
significantly greater numbers of tumour DX5+/CD3- (p<0.001) F4/80+ 
(macrophages) (P<0.001) and CD8+ (P<0.001) cells than control pGT141GMCSF-
B7.1 treated mice. We observed a similar immune profile for the B16F10 treated 
mice (Figure. 5.3). Splenic and tumour CD19+ (p<0.001), DX5+/CD3+ (p<0.01), 
DX5+/CD3- (p<0.01), CD11c+ (dendritic cells) (p<0.001), F4/80 (p<0.001) and 
CD8+ (p<0.001) cells were all significantly higher for the pEEVGMCSF-B7.1 
treated mice than untreated animals. However, we did not observe any significant 
differences in CD4+ or TCR γδ+/CD3+ (γδ T cells) [data not shown]. Notably, when 
the standard pGT141GMCSF-B7.1 therapy was compared to pEEVGMCSF-B7.1 
the percentage of CD19+ (p<0.001), DX5+/CD3+ (p<0.01), CD11c+ (p<0.001) and 
CD8+ (p<0.001) cells were all significantly greater indicating pEEVGMCSF-B7.1 
recruits a superior immune recruitment locally at the tumour site. The spleen data 
had a similar trend as the tumour data with the percentage of CD19+ (p<0.01), 
DX5+/CD3+ (p<0.001), CD11c+ (p<0.001), F4/80 (p<0.001) and CD8+ (p<0.001) 
cells all significantly greater in the pEEVGMCSF-B7.1 treated mice when compared 
to the standard therapy. These data indicate that treatment with pEEVGMCSF-B7.1 
induces robust recruitment of innate and adaptive immune cell populations in both 
colorectal and metastatic melanoma models. 
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Table 5.2: Percentage of immune cells in all tumour and spleen cells present 72 
hours post treatment. Cells were isolated from CT26 tumours and spleens from 
treated and untreated control Balb/C mice. They were analysed by flow cytometry in 
which 20,000 events were recorded. Data represents the mean percentage of CD19+ 
(B cells), DX5+/CD3+ (NKT cells), DX5+/CD3- (NK cells), CD11c+ (DC cells), 
F4/80+ (Macrophage cells), CD4+ and CD8+ (T cells) positive cells at the time of 
analysis (48hours) post treatment. Data represents the mean percentage from 4 mice. 
The asterisks (*) indicate significant values of *p<0.05, **p<0.01, ***p<0.001 as 
determined by one-way ANOVA following Bonferroni’s multiple comparison of 
pEEVGMCSF-B7.1 compared to untreated tumour. The asterisks (●) indicate 
significance values of ●p<0.05, ●●p<0.01, ●●●p<0.001 as determined by one-way 
ANOVA following Bonferroni’s multiple comparison of pEEVGMCSF-B7.1 
compared to the standard vector pGT141GMCSF-B7.1.  
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Table 5.3: Percentage of immune cells in all tumour and spleen cells present 72 
hours post treatment. Cells were isolated from B16-F10 tumours and spleens from 
treated and untreated control C57Bl/6J mice. They were analysed by flow cytometry 
in which 20,000 events were recorded. Data represents the mean percentage of 
CD19+ (B cells), DX5+/CD3+ (NKT cells), DX5+/CD3- (NK cells), CD11c+ (DC 
cells), F4/80+ (Macrophage cells), CD4+ and CD8+ (T cells) positive cells at the time 
of analysis (48hours) post treatment. Data represents the mean percentage from 4 
mice. The asterisks (*) indicate significant values of *p<0.05, **p<0.01, ***p<0.001 
as determined by one-way ANOVA following Bonferroni’s multiple comparison of 
pEEVGMCSF-B7.1 compared to untreated tumour. The asterisks (●) indicate 
significance values of ●p<0.05, ●●p<0.01, ●●●p<0.001 as determined by one-way 
ANOVA following Bonferroni’s multiple comparison of pEEVGMCSF-B7.1 
compared to the standard vector pGT141GMCSF-B7.1.  
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5.5.3 pEEVGMCSF-B7.1 Treatment Dampens Down Suppressive Treg 
Responses 
T regulatory cells (Treg) are key to dampening effector cell responses, and therefore 
represent one of the main obstacles to effective anti-tumour responses. We therefore 
decided to analyse local Treg percentages in B16F10 tumours of treated animals 
(Figure 5.3). In the pEEVGMCSF-B7.1 treatment group (Figure 3.2B), 
CD4+CD25+FoxP3+ (Treg) cell percentage was reduced significantly (p<0.01) 
compared to the untreated group (Figure 5.3A). Interestingly, we also observed a 
CD4+CD25-FoxP3+ tumour cell population, which was also significantly reduced in 
the pEEVGMCSF-B7.1 treated animals when compared to untreated tumours 
(p<0.01), and also therapeutic control pGT141GMCSF-B7.1. These data show that 
electroporation with pEEVGMCSF-B7.1 reduces potentially detrimental suppressive 
tumour Treg populations.  
.
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Figure 5.3: Percentage of the respective T cells found locally at the site of the 
B16F10 tumours treated with pMG, pEEV, pGT141GMCSF-B7.1, and 
pEEVGMCSF-B7.1 or untreated (A) Represents data obtained for the 
CD4+CD25+FoxP3+cells (B) CD4+CD25-FoxP3+ cells. Data represents the mean of 
the respective cells. Error bars show SD from 4 animals. The asterisks (*) indicate 
significant values of *p<0.05 as determined by one-way ANOVA following 
Bonferroni’s multiple comparison of pEEVGMCSF-B7.1 compared to untreated 
tumour. The asterisks (●) indicate significance values of ●p<0.05 as determined by 
one-way ANOVA following Bonferroni’s multiple comparison of pEEVGMCSF-
B7.1 compared to the standard vector pGT141GMCSF-B7.1. Similar results were 
obtained in two independent experiments.  
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5.5.4 Mice Receiving pEEVGMCSF-B7.1 Treatment Have a Pro-Inflammatory 
Cytokine Milieu in Spleens and Tumours  
The cytokine milieu systemically and in the local tumour environment is often 
indicative of prognosis. Thus, we next examined the concentrations of cytokines 
within tumours and spleens in treated; untreated and healthy animals 72 hours post 
treatment (Figure 5.4). Tumour and spleen concentrations of IFN-γ and IL-12 were 
all significantly elevated for the pEEVGMCSF-B7.1 treatments compared to 
untreated (p<0.001), pGT141GMCSF-B7.1 (p<0.001) and all other groups analysed. 
Tumour TNF-α levels were also significantly greater in pEEVGMCSF-B7.1 treated 
mice when compared to untreated (p<0.01), pGT141GMCSF-B7.1 (p<0.05) and all 
other groups analysed. In contrast, IL-10 levels were significantly reduced in 
pEEVGMCSF-B7.1 treated mice (both spleen and tumour) when compared to the 
pGT141GMCSF-B7.1 treated group (p<0.05) and all other groups analysed. Thus, 
pEEVGMCSF-B7.1 treatment appears to drive a strong inflammatory environment 
in both systemic and tumour sites, potentially via modulation of immune cell 
recruitment.  
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Figure 5.4: Cytokine levels (IFN-γ, IL-10, IL-12 and TNF-α) as measured from 
tumour and spleens isolated from B16F10 tumour challenged treated, untreated and 
healthy mice. The error bars represent the mean of 4 individual mice ± the SEM. The 
significance of differences was determined by one-way ANOVA following 
Bonferroni’s multiple comparison (*p<0.05, ** p<0.01, *** p<0.001 untreated 
versus pEEVGMCSF-B7.1 and ●p<0.05, ●●p<0.01, ●●●p<0.001 pGT141GMCSF-
B7.1 versus pEEVGMCSF-B7.1. Similar results were obtained in two independent 
experiments. 
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5.5.5 pEEVGMCSF-B7.1 Treated Mice Have Enhanced NK cell and B Cell 
Responses  
NK cells have been shown to play critical roles in host immunity to cancer. As we 
observed a significant increase in this effector population in both systemic and 
tumour sites, we further characterised their response in B16F10 challenged mice. We 
observed that NK cells positive for IFN-γ were significantly higher (p<0.001) in the 
pEEVGMCSF-B7.1 treated groups when compared to untreated and pEEV control 
tumours (Figure 3.3). We observed a similar trend in the splenic NK population with 
significantly elevated levels of IFN-γ positive NK cells compared to the untreated 
and healthy mice. Importantly when we analysed CD107a (LAMP-1), which is a 
sensitive marker of NK cell degranulation/cytotoxic activity, we observed 
significantly higher (p<0.001) levels of CD107+ NK cells in pEEVGMCSF-B7.1 
treated groups when compared to untreated and pEEV control tumours. The role of B 
cells in anti-tumour responses has been somewhat overlooked; however B cells can 
function as effector cells that mediate tumour immunity and destruction. 
Interestingly, we observed a significant increase in B cell percentages (both spleen 
and tumour; Table 5.2) and upon further investigation we noted that there was also a 
significant increase in B cells positive for IL-12 in pEEVGMCSF-B7.1 treated 
groups when compared to controls (Figure 5.5). These data indicate that 
pEEVGMCSF-B7.1 promotes the activation and function of NK cells and B cells 
during B16F10 challenge. 
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Figure 5.5: Cytotoxicity of NK and B cells in tumour and spleens of treated 
C57BL/6J mice. Data represents the mean of the respective cells. Error bars show 
SD from 4 animals. The asterisks (*) indicate significant values of *p<0.05, *p 
<0.01, ***p<0.001 as determined by one-way ANOVA following Bonferroni’s 
multiple comparison pEEVGMCSF-B7.1 compared to untreated tumour. The 
asterisks (●) indicate significance values of ●●p<0.01 and ●●●p<0.001 as determined 
by one-way ANOVA following Bonferroni’s multiple comparison of pEEVGMCSF-
B7.1 compared to the untreated groups. Similar results were obtained in two 
independent experiments. 
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5.5.6 pEEVGMCSF-B7.1 Treatment Also Promotes Antigen-specific Secondary 
Tumour Protection Upon Re-challenge  
There is strong evidence that links positive prognosis with robust tumour immune 
infiltrate in several different cancer types. As we observed a superior immune 
response after pEEVGMCSF-B7.1 treatment (Figure 5.3A and B), which was linked 
to reduced or absent primary tumours, we next challenged these mice (both CT26 
and B16F10 cured and naive mice) to determine overall tumour protection. To 
compare tumour growth of ‘cured mice’, naive age-matched mice were inoculated 
with the same dose of viable tumour cells (Figure 5.6A and E). To determine tumour 
specific protection a different tumour was selected and cured and naive mice were 
challenged with either Lewis lung cancer (LLC) or Breast cancer (4T1). We 
observed long term (100 days) tumour-specific protection in pEEVGMCSF-B7.1 
treated ‘cured’ mice group, both for the CT26 and B16F10 models. Notably, we 
observed that tumour protection was limited to the CT26 or B16F10 and not the 
previously unexposed tumours such as 4T1 and LLC in the respective models. This 
data suggests that pEEVGMCSF-B7.1 treatment results in a durable response.  
To further confirm an antigen-specific response, we next determined the in 
vitro cytotoxicity of mixed splenic T lymphocyte population against CT26 and 
B16F10 cells. (Figure 5.6B and F). Cytotoxic responses of splenic T lymphocytes 
were significantly greater against CT26 and B16F10 cells from pEEVGMCSF-B7.1 
treated ‘cured’ mice than in naive mice. To determine the specificity of this 
cytotoxicity we included the unexposed tumours 4T1 and LLC for the respective 
model. The splenic T lymphocytes against the CT26 and B16F10 demonstrated low 
percentage cytotoxicity. These results correspond with the observed immunity in 
vivo (Figure 5.6A and E). 
The possible development of an immune mediated anti-tumour activity 
following pEEVGMCSF-B7.1 was further tested by a modified Winn assay 
(adoptive transfer), where groups received subcutaneous inoculation of a CT26 or 
B16F10 cell mixture and splenocytes from pEEVGMCSF-B7.1 treated ‘cured’ mice 
or naive mice, a mixture of 4T1 or Lewis lung cells and splenocytes from 
pEEVGMCSF-B7.1 treated ‘cured’ mice or naive mice, 4T1 or LLC and CT26 or 
B16F10 in their respective model (Figure 5.6C and G). All mice inoculated with 
splenocytes from naive mice developed tumours. Mice inoculated with mixtures of 
splenocytes and 4T1 or Lewis lung developed tumours, whereas no tumour growth 
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was observed in mice inoculated with splenocytes from pEEVGMCSF-B7.1 treated 
‘cured’ mice in both the CT26 and B16F10 models indicating the protective effect 
was antigen specific as observed in the in vitro analysis. Control groups which were 
inoculated with CT26, B16F10, 4T1 or LLC cells all developed tumours and 
indicated that the tumours were growing in the correct manner. The tumour 
protective effect in the mice inoculated with splenocytes from pEEVGMCSF-B7.1 
treated ‘cured’ mice in both the CT26 and B16F10 models resulted in prolonged 
survival (150 days). We also observed significantly high levels of IFN-γ from 
animals who received adoptively transferred mixtures of both CT26 and B16F10 and 
splenocytes from the pEEVGMCSF-B7.1 treated ‘cured’ mice of the respective 
model and naive mice of the same age (Figure 5.6D and H). This suggests adoptive 
transfer to naive mice of specific anti-tumour immune response provided protection 
to tumour challenge.         
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Figure 5.6: Tumour protection, cytotoxicity and immune memory. (A) Tumour 
protection was observed in the pEEVGMCSF-B7.1 treated CT26 mice when 
challenged (s.c.) with 1 x106 tumour cells (Balb/C n=6/group). ‘Cured’ and naive 
mice were challenged with CT26 and 4T1 tumour cells. Mice were monitored for 
tumour development. 100% survival was observed in the CT26 cured mice 
challenged with CT26. All other groups were sacrificed due to tumour burden by day 
25. Similar results were obtained in two independent experiments.  (B) 
Augmentation of the in vitro cytolytic activities of the spleen after pEEVGMCSF-
B7.1 treatment of CT26 tumours. Groups included CT26, 4T1 cells, and Naive and 
‘CT26 cured’ splenocytes incubated with CT26 and 4T1 cells respectively. The 
highest cytotoxicity was observed in the CT26 cells incubated with splenocytes 
obtained from ‘CT26 cure’ mice treated with pEEVGMCSF-B7.1. The data shown 
represents one of two separate experiments with similar results (n=6/group). (C) 
Adoptive transfer of lymphocytes of CT26 study. Mice (n=6) received subcutaneous 
injections of a mixture of mice receiving CT26 cells and splenocytes either from 
cured or naive mice, a mixture of 4T1 cells and splenocytes either from cured or 
naive mice, CT26 cells only or 4T1 cells only. All mice receiving mixtures of CT26 
cells and splenocytes either from cured or pEEVGMCSF-B7.1 treatment survived up 
to 150 days whereas tumours developed in all animals within the other groups. (D) 
Interferon gamma production measured from supernatents obtained from stimulated 
splenocytes collected from re-challenged - adoptive transfer survivors (50 days post) 
and naive animals and IFN-γ was measured. High levels of IFN-γ were produced by 
pEEVGMCSF-B7.1 treated mice. The y-axis represents the concentration of IFN-γ 
in pg/ml of the supernatant from the stimulated splenocytes. Error bars show SD 
from 6 animals. (E) Tumour protection was observed in the pEEVGMCSF-B7.1 
treated B16F10 mice when challenged (s.c.) with 2 x105 tumour cells (C57BL/6J 
n=6/group) in the left flanks. ‘Cured’ and naive mice were challenged with B16F10 
and Lewis lung tumour cells. These mice were observed for tumour development. 
100% survival was observed in the B16F10 cured mice challenged with B16F10. All 
other groups were sacrificed due to tumour burden by day 28. Similar results were 
obtained in two independent experiments. (F) Augmentation of the in vitro cytolytic 
activities of the spleen after pEEVGMCSF-B7.1 treatment of B16F10 tumours, the 
specific cytotoxicity was greatest at an effector target ratio of 50:1 after 48 hours 
incubation. Groups included B16F10, Lewis lung cells, and Naive and ‘B16F10 
cured’ splenocytes incubated with B16F10 and Lewis lung cells respectively. The 
highest cytotoxicity was observed in the B16F10 cells incubated with splenocytes 
obtained from ‘B16F10 cure’ mice treated with pEEVGMCSF-B7.1. The data shown 
represents one of two separate experiments with similar results (n=6/group). (G) 
Adoptive transfer of lymphocytes of B16F10 study. Mice (n=6) received s.c. 
injections of a mixture of B16F10 cells and splenocytes either from cured or naive 
mice, a mixture of Lewis lung cells and splenocytes either from cured or naive mice, 
B16F10 cells only or Lewis lung cells only. All mice receiving mixtures of B16F10 
cells and splenocytes either from cured from pEEVGMCSF-B7.1 treatment survived 
up to 150 days whereas tumours developed in all animals within the other groups. 
(H) Interferon gamma production measured from supernatents obtained from 
stimulated splenocytes collected from re-challenged - adoptive transfer survivors 
(approx 50 days post) and naive animals and IFN-γ was measured. High levels of 
IFN-γ were produced by pEEVGMCSF-B7.1 treated mice. The y-axis represents the 
concentration of IFN-γ in pg/ml of the supernatant from the stimulated splenocytes. 
Error bars show SD from 6 animals.   
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5.6 Discussion 
Cancer treatment strategies utilising immunotherapy have recently gained clinical 
traction with the positive results emanating from Ipilimumab antibody clinical 
studies. The use of DNA plasmid based gene therapy for immunotherapy has also 
showed promise with encouraging data reported with IL-12 delivered via 
electroporation to patients with malignant melanoma [23].  
We have developed a DNA plasmid which enables the enhanced expression 
of exogenous genes in transfected cancer cells. The pEEV was used to deliver via 
electroporation DNA encoding for GMCSF and B7.1 (pEEVGMCSF-B7.1) which 
we have demonstrated protects from primary and secondary tumour growth in both 
colon adenocarcinoma and melanoma cancer models by generating a robust pro-
inflammatory immune cell recruitment and cytokine environment in systemic and 
tumour compartments.  
Previously we have shown that delivery of our EEV plasmid (pEEV) via 
electroporation is capable of achieving reliable and superior expression in a variety 
of murine and porcine tissue types when compared to a control plasmid [25]. We 
therefore decided to engineer pEEV to contain the immune therapeutic genes; 
GMCSF and B7.1 and test efficacy in 2 aggressive cancer models. As already 
highlighted GMCSF and B7.1 are key molecules in inducing robust immune 
responses, which may facilitate subsequent anti-tumour immunity [26, 27]. Indeed, 
only those mice treated with pEEVGMCSF-B7.1 were observed to have reduced or 
absent primary tumour growth which paralleled to significantly improved survival 
rates. Mice treated with pEEVGMCSF and pEEVB7.1 delivered singly had 
minimal/no therapeutic effect (Data not shown). Correspondingly, when we analysed 
immune populations we observed that pEEVGMCSF-B7.1 treatment induced a 
significant increase in the levels of innate and adaptive immune cells both 
systemically and within the tumour environment. More specifically, increases in DC 
and macrophage levels were observed and may correspond to the presence of high 
GMCSF expression after pEEVGMCSF-B7.1 transduction, as previous studies have 
shown that GMCSF-/- mice have reduced DC and macrophage recruitment and 
survival [29, 30].  Several studies have also indicated that B cells can respond to 
GMCSF [31]. Within cancer immunology, B cells are currently under investigated, 
but appear to have a complex role. Interestingly, we observed that B cell populations 
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were increased after pEEVGMCSF-B7.1 treatment and upon further examination we 
observed that they had increased expression of IL-12 which correlated with total 
tissue levels of IL-12 in the spleen and tumour tissues of treated mice. IL-12 is a 
potent pro-inflammatory and anti-angiogenic cytokine capable of activating multiple 
aspects of innate and adaptive anti-tumour immunity, particularly via modulation of 
IFN-γ [32]. Indeed, we also observed increased tissue IFN-γ levels after 
pEEVGMCSF-B7.1 treatment, which potentially corresponds with the high levels of 
IFN-γ+ NK cells in pEEVGMCSF-B7.1 treated mice. Importantly IL-12 and indeed 
GMCSF are also able to regulate NK cell mediated cytotoxicity. NK cells are critical 
innate cells during cancer as they able to distinguish and destroy malignant from 
healthy cells, which is controlled by complex interactions of inhibitory and 
activating receptors which trigger specialised downstream effector signalling 
pathways [33, 34]. Importantly, we also observed a significant increase in NK cell 
levels and in tandem a high proportion expressing CD107a (cytotoxicity marker) in 
those mice treated with pEEVGMCSF-B7.1, highlighting the potential for 
pEEVGMCSF-B7.1 treatment to induce IL-12 expressing B cells which in turn 
potentially induces potent NK cell tumour killing and NK-derived IFN-γ production. 
Thus, these data emphasises the importance of the presence of these cell populations 
for cancer treatment and prognosis.   
An overall reduction in tumour resident Tregs is indicated as a positive 
response for any cancer therapy [5]. Tregs cells are important regulators of immune 
cells and are seen as immune suppressors [5, 26]. Thus, any reduction of T09wq has 
the potential to allow immune cell recruitment, to the tumour site. pEEVGMCSF-
B7.1 treatment correlates with Treg reduction with corresponding improved cellular 
infiltration. Interestingly, we also observed a CD4+CD25-FoxP3+ population which 
was significantly reduced after pEEVGMCSF-B7.1 treatment. Previous studies have 
suggested that this population may act as a reservoir/precursor of 
CD4+CD25+FoxP3+ Tregs, thus this reduction may assist in the reduced levels of 
Tregs present in our treated tumours [26]. Importantly, Treg cells also contribute to 
the production of immunoregulatory cytokines, such as IL-10 [35]. IL-10 is an 
immune-suppressing anti-inflammatory cytokine and is up regulated in many cancer 
models. Additionally, IL-10 down regulates the expression of TH1 cytokines, such as 
IL-12 and IFN-γ and induces a Treg response [35, 36]. This reduced level of IL-10 
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observed in the pEEVGMCSF-B7.1 treated group correlates with the reduced levels 
of Treg cells and supports the positive inflammatory responses of this therapy. 
The goal of all anti-cancer therapies is long-lasting responses that also 
prevent metastases and secondary tumours. As we observed such potent cellular and 
cytokine responses after pEEVGMCSF-B7.1 treatment we studied outcomes after 
tumour re-challenge. Notably, all naive mice succumbed to disease, while those in 
the pEEVGMCSF-B7.1 group developed no tumours suggesting protective and long-
lasting immunity. As already discussed GMCSF is known to mature both DC and 
macrophages for antigen presentation. During our studies an antigen specific 
immune response was indeed suggested, as tumour protection and in vitro killing 
was limited to the CT26 or B16F10 and not to the previously unexposed tumours 
such as 4T1 and LLC in the respective models. Furthermore DCs and macrophages 
require help from NK cells for maturation, proper antigen presentation function and 
priming of T cell responses [37]. This bi-directional crosstalk during the early phases 
of tumour immunity as indicated by our data may also influence the following type 
and magnitude of adaptive immune response to pEEVGMCSF-B7.1. B cells are also 
important in antigen presentation to T cell populations.  Indeed previous studies have 
indicated that activated B cells can be used as effective APCs for T-cell sensitisation 
to tumour antigens [38]. IL-10 has been shown to directly affect the function of 
antigen-presenting cells by inhibiting the expression of MHC and co-stimulatory 
molecules [39, 40], which in turn induces immune suppression or tolerance [41], 
thus reduced levels in to pEEVGMCSF-B7.1 treated mice may also correspond to 
robust antigen-specific immunity. 
Although we did not investigate this mechanism of re-challenge protection in 
great detail (using mixed lymphocyte preps) we postulate that the anti-tumour 
generated immunity could be due to the action of a few different cell types. The 
protection could be antigen specific B cells producing cytokines that activate NK and 
T cell killing, and indeed a previous study has indicated that B cells may mediate 
tumour regression/protection after adoptive immunotherapy of solid tumours [42]. 
Finally, antigen-specific T cell responses, which are well known to be absolutely 
crucial for comprehensive anti-cancer immunity and eradication of tumours, would 
be a highly likely protective immune mechanism [5]. Clinically this protective nature 
is a very important observation. Recurring tumours post treatment is a major issue 
that exists with standard treatments like surgery with tumour cells left behind in 
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postoperative margins. This observation again supports the importance of this 
treatment and as its potential clinical adaption. 
Importantly, the electrogene therapy with pEEVGMCSF-B7.1 protocol 
appears to be safe and non-toxic. All mice remained healthy throughout the course of 
the experiments and there were no treatment-related deaths. This suggests that 
electroporation of the solid tumours is well tolerated and the transgene expression 
did not induce systemic toxicity. Also, it was observed that long term survival of 
mice had no evidence of autoimmune disease, suggesting that, in this model, 
immune clearance of tumours could be achieved while maintaining autoimmune 
control. 
Our findings suggest that the strategy of using pEEV as a therapeutic plasmid 
coding for two immunogenes, GMCSF and B7.1, in combination with 
electroporation compared to plasmids using the CMV promoter was far superior. The 
treatment established potent, durable tumour immunity and had a curative effect in 
two tumour models tested. As indicated above a robust immune response is 
important in cancer treatment outcome and prognosis. We demonstrated that 
pEEVGMCSF-B7.1 did induce a strong immune response, including enhanced B 
and NK cell responses. We can conclude that immunogene therapy of solid tumours 
by pEEV in combination of electroporation results in containment of the tumour. 
This strategy could be developed for clinical application. 
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Chapter 6 
General Discussion 
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In any disease condition, progress is dependent on an accurate diagnosis. If it were 
not possible to identify a disease, then the discovery of its causes, prediction of its 
outcomes, selection of appropriate treatments and the conduction of clinical trials 
becomes fraught with difficulty. When viewed in this context, cancer is a remarkably 
heterogeneous group of diseases.  
For more than a century, we have classified cancers by their tissue or organ 
of origin e.g. breast/colon – and our therapies have been tailored accordingly. More 
recently, as our understanding of cancer cell biology has improved, we have 
developed a growing appreciation of cancer as a systemic disease [1, 2].  However, 
our improved understanding has been closely matched by cancer cell evolution [3-7]. 
Armed with the capacity for immune evasion, genetic instability and multidrug 
resistance [5-9], to name but a few, it is becoming increasingly clear that the future 
of anti-cancer therapies lies in a multi-modal approach.  
In this thesis, we have adopted a “three-legged stool” approach to anti-cancer 
therapy. The first leg encompasses primary tumour ablation. Presently, tumour 
ablation is primarily reliant on surgical excision. However, while surgical resection 
has proven to be effective in the control of primary tumours and early-stage disease, 
a number of issues still need to be resolved. Advanced stage disease at presentation, 
anatomical locations that preclude complete excision as well as the presence of 
intercurrent illnesses all limit the application or adversely alter the risk-benefit 
profile of surgery [10-15]. Furthermore, although surgical resection confers 
statistically significant survival benefits over other therapeutic modalities, in the 
management of certain cancers such as cancers of the pancreas, lung and bronchus, it 
is still often associated with poor overall clinical outcomes [16-18]. 
 To this extent, minimally invasive tumour ablation is a valuable clinical 
option in the anti-cancer arsenal. The efficiency of electroporation in tumour ablation 
has been reported by multiple investigators [19-21]. Clinical experience with 
reversible electroporation has been published extensively as a therapy that improves 
tissue permeability to specific chemotherapeutic agents providing local control of 
cutaneous cancers unsuitable for surgery and resistant to chemo/radiotherapy [22-
32]. To date, the equipment available for electroporation limited its clinical utility to 
the treatment of cutaneous and subcutaneous tumour nodules.  To address this need, 
we developed the EndoVe device, enabling endoscopic electroporation of 
gastrointestinal tissues and tumours. We conducted a pre-clinical evaluation of the 
173 
 
EndoVe prior to a phase I/II clinical study and validated the efficacy of the system in 
the treatment of cutaneous murine gastrointestinal tumours. In addition, we 
established the safety and utility of endoscopically-delivered electroporation through 
evaluation in a porcine model and by treating canine colorectal tumours.  
The second leg of our stool involved immunotherapy – harnessing and 
enhancing the innate powers of the immune system to fight cancer. There are still 
many unmet needs in cancer, especially for patients with advanced, metastatic 
disease. In recent years, immunotherapies have succeeded in making significant 
advances in the treatment of patients with cancers previously considered incurable. 
The main types of immunotherapy presently employed in clinical practise include 
monoclonal antibodies, anticancer vaccines and non-specific immunotherapies.  
Specifically, significant advances have been made in the management of 
malignant melanoma, known to be an immunogenic tumour.  Between 2011 and 
now, the United States Food and Drug Authority (FDA) has approved seven novel 
agents, including Ipilimumab (anti-CTLA-4 antibody), Nivolumab (programmed 
death receptor-1 (PD-1) checkpoint inhibitor), Vemurafinib (BRAF-inhibitor) and 
Trametinib (MEK-inhibitor) intended to be used in advanced cases of melanoma. In 
phase II and III randomized trials on patients with previously treated metastatic 
disease, Ipilimumab, with or without a peptide vaccine, was found to improve 
overall survival [33-38].  More recently, Nivolumab, a programmed death receptor-1 
(PD1-1) checkpoint inhibitor was shown either alone, or in combination with 
Ipilimumab, to be associated with significantly longer progression-free survival than 
Ipilimumab alone [39-42]. Moreover, a subset of patients with malignant melanoma 
has been found to carry the c-Kit mutation, traditionally associated with chronic 
myelogenous leukaemia. Early studies have demonstrated that treating this subset of 
patients with Imatinib, a tyrosine kinase inhibitor, demonstrated complete resolution 
of distant, established metastatic disease [43-48]. 
These immunologic advances are not limited to malignant melanoma alone.  
Prostate cancer was the first cancer type where the FDA approved the use of an anti-
cancer vaccine, Sipuleucel-T based on observed survival benefits [49-51]. 
Furthermore, between a third and a quarter of patients with glioblastoma have been 
shown to carry the Epidermal Growth Factor Receptor vIII (EGFRvIII) mutation. 
Expression of EGFRvIII has been shown to correlate to increased tumourigenicity in 
mouse models and poor long term survival in clinical studies of patients. These 
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patients would traditionally have been treated with surgery followed by 
chemoradiotherapy. However, recent studies have demonstrated that vaccination 
with Rindopepimut has been shown to specifically eliminate cells expressing 
EGFRvIII. Rindopepimut stimulates the patient’s immune system, inducing 
pronounced EGFRvIII-specific humoral and cellular responses. Phase II clinical 
trials have suggested that vaccination of newly diagnosed glioblastoma patients with 
Rindopepimut plus adjuvant granulocyte-macrophage colony-stimulating factor 
(GMCSF) resulted in prolonged progression-free and overall survival with minimal 
toxicity [52-56].  
Many of the immune suppressive regulatory circuits that operate in tumours 
are part of the physiologic regulatory mechanisms used by the immune system to 
maintain homeostasis to prevent autoimmunity and temper inflammation after 
infection or injury [57-60]. Within this context, a number of studies exist describing 
the presence and accumulation of Treg in tumours. This accumulation increases with 
tumour volume and is coupled with the inhibition of innate immune rejection of the 
tumour and precludes the proliferation of effector cells leading to an overall poor 
prognosis [57-60]. Building on these observations we opted for a combination 
regime of Treg depletion with anti-CD25 antibodies and immunotherapy with the 
cytokine, pGMCSF-B7.1 While we observed a modest but significant improvement 
of primary tumour burden and survival for each individual treatment given alone or 
for the combination treated groups, the combination regime had the remarkable 
effect of eradicating pre-existing, established lung metastases when compared to the 
use of either treatment alone.  This would indicate that the combination of Treg 
suppression with pGMCSF-B7.1 immunotherapy allowed for an enhanced anti-
tumour CD8 immune response with the decrease in the levels of metastatic nodules. 
The potential clinical implications of this should not be understated as, for almost 2 
centuries, scientists have been labouring to understand metastases, which account for 
nine out of ten cancer deaths, to finally disarm the latent enemy.  
One of the principal challenges of immune therapy for cancer will be to 
establish novel treatments for those patients who do not carry the genetic mutations 
currently targeted by immune therapies and to minimise the side effect profile 
associated with the immune therapies which already exist [61-63]. While survival is 
the most important endpoint for evaluating cancer therapy, objective criteria based 
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on changes in the size of the tumour mass need to be developed in order to avert the 
danger of underestimating the efficacy of emerging immune therapies.  
The third and final leg of our anti-cancer strategy involved the development 
of a safe, novel, non-viral enhanced expression vector system to facilitate the 
cytoplasmic delivery of therapeutic genes. Non-viral plasmid DNA gene therapy 
represents a promising approach for the treatment of many diseases including cancer. 
Intracellular delivery of DNA can be achieved with the application of 
electroporation, facilitating the initial transport of exogenous DNA across the 
hydrophobic cell membrane into the cytoplasm [19-21, 64]. Heretofore, the variable 
rates of subsequent transport of DNA from the cytoplasm to the nucleus for mRNA 
expression resulted in varying degrees of exogenous gene translation and proved a 
major limitation when compared to the high transfection rates associated with viral 
vectors. To overcome these expression difficulties, we developed a DNA-based 
enhanced expression vector (pEEV), with improved expression capabilities across a 
range of tissue histologies over standard non-viral DNA vectors. The anti-tumour 
effects of pEEV were demonstrated by the delayed growth and increased survival of 
the non-therapeutic pEEV-treated CT26 tumour model.  
Having developed and established the DNA-based pEEV vector, we 
engineered pEEV to contain the immune therapeutic genes GMCSF and B7.1. The 
anti-tumour efficacy of electroporated pEEV plasmid, coding for GMCSF and the 
B7-1 co-stimulatory immune molecule (pEEVGMCSF-B7.1) in growing solid 
tumours was investigated and compared to a standard plasmid. pEEVGMCSF-B7.1 
treatment was found to significantly enhance levels of both innate and adaptive 
immune populations in tumour and systemic sites, which corresponded to 
significantly increased tissue levels of pro-inflammatory cytokines including IFN-γ 
and IL-12. In contrast pEEVGMCSF-B7.1 treatment significantly reduced T 
regulatory populations and also the anti-inflammatory cytokine IL-10. Our data 
indicated that electro-immunogene therapy with the non-viral pEEVGMCSF-B7.1 
was able to induce potent and durable anti-tumour immune responses that 
significantly reduce primary and also secondary tumour growth and thus represents a 
solid therapeutic platform for pursuing future clinical trials.  
In this thesis, we demonstrated the viability and pre-clinical validation of 
EndoVe-mediated endoscopic electrochemotherapy as an alternative to surgery for 
primary tumour ablation. Furthermore, we demonstrated that while a combination of 
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Treg depletion and immunogenetherapy with GMCSF significantly delayed primary 
tumour growth, its most significant effect was in the eradication of pulmonary 
metastases in the B16-F10 murine melanoma model. This is significant for two 
reasons. Firstly, the B16-F10 melanoma model is known to be a poorly 
immunogenic, highly aggressive model for murine tumour immunotherapy studies 
[65]. Additionally, while primary tumours are often amenable to surgical excision or 
debulking, 9 out of 10 patients with melanoma die from their metastatic disease 
burden. In Chapter 4, we developed a novel, non-viral pEEV vector system, 
achieving mRNA expression levels far superior to those observed using conventional 
plasmid DNA vectors. Following on from this observation, we then utilised this 
pEEV vector system in combination with the immune cytokine GMCSF-B7.1 
leading to robust recruitment of immune effector cells with consequent potent, 
durable and transferable tumour antigen-specific responses. 
      We would foresee the future directions of this thesis incorporating expansion of 
the use of endoscopic electrochemotherapy to target a variety of intraluminal tissues 
and tumours. Furthermore, novel therapies are needed for patients who do not carry 
the genetic mutations currently targeted by immune therapies. In addition, coupling 
of electrochemotherapy with immune-potentiating agents such as checkpoint 
blockade ligation or iCos agonists may facilitate enhanced anti-tumour responses. 
When President Richard Nixon declared war on cancer in 1971, no one could 
have imagined the true magnitude of the undertaking. Some four decades on, we 
have made meaningful strides in the battle against this mortal enemy, yet millions 
still die from cancer each year. It is my belief that we are seeing a paradigm shift in 
cancer therapy, where the focus has moved to targeting and harnessing the immune 
system as opposed to targeting the tumour itself. Characterisation of the molecular 
identities of a number of tumour-associated antigens has provided a major stimulus 
for the development of new immunotherapies for the treatment of patients with solid 
cancers. However, we need to be cautious about coalescing anecdotal stories of 
success into data.  
It is my sincere hope that we may be the generation to finally weed out the 
cancer cell from its reluctant host. However, it is critical that when we explore and 
shape this dialogue on cancer, we do not lose sight of the broader view of health, 
incorporating quality of life, the sociological and psychological impact of this 
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tremendous disease on the patient and their families, and the interplay of other co-
morbidity with cancer. 
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